Covid-19 Breakthrough Infections in Vaccinated Health

New England Journal of Medicine
385, 1474-1484
DOI: 10.1056/nejmoa2109072

Citation Report

#	Article	IF	Citations
1	Parkinsonismâ€"New drugs and new approaches. Disease-a-Month, 1979, 25, 1-51.	0.4	1
2	Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients. Indian Journal of Medical Research, 2021, 153, 559-561.	0.4	1
10	A blood marker predicts who gets â€˜breakthroughâ€™ COVID. Nature, 2021, , .	13.7	3
22	Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary. Journal of Infection, 2021, 83, 559-564.	1.7	66
25	Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. Cancers, 2021, 13, 4191.	1.7	34
28	Breakthrough Infection among Fully Vaccinated Physicians Working in COVID-19 Treatment Centers; Prevalence, Presenting Symptoms, Co-Morbidities and Outcome in the Third Wave of Epidemics in Myanmar. Journal of Biomedical Research & Environmental Sciences, 2021, 2, 721-730.	0.1	0
33	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. Scientific Reports, 2021, 11, 17325.	1.6	27
36	Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Blood Cancer Discovery, 2021, 2, 577-585.	2.6	44
37	Changes in Mental Health and Preventive Behaviors before and after COVID-19 Vaccination: A Propensity Score Matching (PSM) Study. Vaccines, 2021, 9, 1044.	2.1	26
38	A closer look at U.S COVID-19 vaccination rates and the emergence of new SARS-CoV-2 variants: It's never late to do the right thing. Annals of Medicine and Surgery, 2021, 69, 102709.	0.5	4
40	Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Frontiers in Immunology, 2021, 12, 742914.	2.2	52
41	Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. JAMA - Journal of the American Medical Association, 2021, 326, 1400.	3.8	160
42	A SARSâ€CoVâ€2 Neutralization Assay using Single Molecule Arrays. Angewandte Chemie, 0, , .	1.6	5
43	The perspective of undergraduate dental students on web-based learning in pediatric dentistry during the COVID-19 pandemic: a Korean multicenter cross-sectional survey. BMC Medical Education, 2021, 21, 505.	1.0	13
45	Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response. Vaccines, 2021, 9, 977.	2.1	12
46	Protecting kidney transplant recipients against SARS-CoV-2 infection: A third dose of vaccine is necessary now. American Journal of Transplantation, 2022, 22, 1275-1276.	2.6	13
48	SARS-CoV-2 seroprevalence among 7950 healthcare workers in the Region of Southern Denmark. International Journal of Infectious Diseases, 2021, 112, 96-102.	1.5	8
51	Clinical Outcomes of Adult Patients Hospitalized with COVID-19 after Vaccination. Tropical Medicine and Infectious Disease, 2021, 6, 175.	0.9	10

#	Article	IF	Citations
55	Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. Vaccines, 2021, 9, 1092.	2.1	96
57	Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine. Journal of Infection, 2022, 84, 248-288.	1.7	6
58	Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2022, 79, 137-139.	2.1	12
61	Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients. Viruses, 2021, 13, 1743.	1.5	15
63	Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New England Journal of Medicine, 2021, 385, 1629-1631.	13.9	41
67	Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open, 2021, 6, 100283.	2.0	39
68	Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021. Vaccine, 2021, 39, 5456-5460.	1.7	37
69	Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1885-1888.	1.4	19
70	Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. Journal of Clinical Investigation, 2021, 131, .	3.9	44
71	A SARSâ€CoVâ€2 Neutralization Assay Using Single Molecule Arrays. Angewandte Chemie - International Edition, 2021, 60, 25966-25972.	7.2	21
72	Exploring the possible link between myocarditis and mRNA COVID-19 vaccines. European Journal of Internal Medicine, 2021, 92, 28-30.	1.0	9
73	Controversy surrounding the Sputnik V vaccine. Respiratory Medicine, 2021, 187, 106569.	1.3	28
74	Post-SARS-CoV-2 vaccination specific antibody decrease â€" Thresholds for determining seroprevalence and seroneutralization differ. Journal of Infection, 2021, 83, e4-e5.	1.7	20
75	The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay. International Journal of Infectious Diseases, 2021, 111, 65-67.	1.5	5
76	Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. International Journal of Infectious Diseases, 2021, 112, 40-44.	1.5	31
77	An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine, 2021, 41, 101143.	3.2	78
79	Circadian rhythms in infectious diseases and symbiosis. Seminars in Cell and Developmental Biology, 2022, 126, 37-44.	2.3	7
80	Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection. JAMA Network Open, 2021, 4, e2128568.	2.8	658

#	Article	IF	Citations
81	mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€“Specific T Cells Persist at 6 Months and Recognize the Delta Variant. Clinical Infectious Diseases, 2022, 75, e898-e901.	2.9	25
83	Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination. Vaccines, 2021, 9, 1145.	2.1	20
84	Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose. CKJ: Clinical Kidney Journal, 2022, 15, 226-234.	1.4	30
86	Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity. Science Immunology, 2021, 6, eabi8635.	5.6	24
87	SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker. Journal of Infection, 2022, 84, 418-467.	1.7	2
88	mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science, 2021, 374, abm0829.	6.0	609
89	An ethical analysis of vaccinating children against COVID-19: benefits, risks, and issues of global health equity. Wellcome Open Research, 0, 6, 252.	0.9	3
90	Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks. Vaccines, 2021, 9, 1130.	2.1	36
91	COVID-19 vaccination in patients receiving dialysis. Nature Reviews Nephrology, 2021, 17, 788-789.	4.1	13
93	Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use. Journal of Infection, 2021, , .	1.7	8
95	Rate of Serum SARS-CoV-2 Antibody Decline for Two mRNA Vaccines. journal of applied laboratory medicine, The, 2022, 7, 625-627.	0.6	7
96	U.S National Institutes of Health funding towards SARS-CoV-2 prevention and therapeutic scientific efforts: Is it enough?. Annals of Medicine and Surgery, 2021, 70, 102780.	0.5	0
97	Countering more virulent SARS-CoV-2 variants will require a smarter pandemic response. Cmaj, 2021, 193, E1633-E1634.	0.9	1
98	Secondary Cases of Delta Variant Coronavirus Disease 2019 Among Vaccinated Healthcare Workers With Breakthrough Infections is Rare. Clinical Infectious Diseases, 2022, 75, e895-e897.	2.9	10
101	Vaccinated Patients Admitted in ICU with Severe Pneumonia Due to SARS-CoV-2: A Multicenter Pilot Study. Journal of Personalized Medicine, 2021, 11, 1086.	1.1	9
102	Distinct neutralization profile of spike variants by antibodies induced upon <scp>SARSâ€CoV</scp>â€2 infection or vaccination. American Journal of Hematology, 2022, 97, E3.	2.0	12
103	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. Ageing Research Reviews, 2022, 73, 101494.	5.0	11
104	Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. Blood Advances, 2022, 6, 148-151.	2.5	15

#	Article	IF	Citations
105	SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies. Diagnostic Microbiology and Infectious Disease, 2022, 102, 115565.	0.8	2
106	Early clinical trial data and realâ€world assessment of COVIDâ€19 vaccines: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2021, 41, 837-850.	1.2	6
109	Expert consensus on COVID-19 vaccination in children. World Journal of Pediatrics, 2021, 17, 449-457.	0.8	21
110	Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. Lancet Rheumatology, The, 2022, 4, e11-e13.	2.2	31
111	Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Diseases, 2022, 75, e774-e782.	2.9	5
112	Humoral response to SARS-CoV-2 vaccines in people living with HIV. Infection, 2022, 50, 617-623.	2.3	37
115	Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient. Vaccines, 2021, 9, 1140.	2.1	3
116	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine, 2021, 27, 2127-2135.	15.2	450
117	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	6.9	189
118	Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up. Internal and Emergency Medicine, 2021, , 1.	1.0	25
120	Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of Medicine, 2021, 385, e84.	13.9	1,394
121	A position statement and practical guide to the use of particulate filtering facepiece respirators (N95,) Tj ETQq1 1 0.784314 rgBT /Ov Mycobacterium tuberculosis and SARS-CoV-2. African Journal of Thoracic and Critical Care Medicine, 2021, 26, .	0.3	5
122	Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workersâ€“ A multicenter cohort study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102306.	1.8	15
123	Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease. IScience, 2021, 24, 103219.	1.9	12
124	Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6Âmonths cross-sectional study. Journal of Neuroimmunology, 2021, 361, 577746.	1.1	63
125	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	5.7	123
126	COVID-19 vaccine â€“ Long term immune decline and breakthrough infections. Vaccine, 2021, 39, 6984-6989.	1.7	77
127	Immunogenicity and safety of the BNT162b2 mRNA COVIDâ€19 vaccine in haematopoietic stem cell transplantation recipients. British Journal of Haematology, 2022, 196, 884-891.	1.2	48

#	Article	IF	Citations
128	Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?. European Journal of Internal Medicine, 2021, 94, 105-107.	1.0	14
129	Breakthrough Infection With Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Delhi: A Single-Institution Study. Cureus, 2021, 13, e19070.	0.2	9
130	Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2. , 2022, 233, 108027.		2
131	Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA - Journal of the American Medical Association, 2021, 326, 2524.	3.8	88
132	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. Medicinski Podmladak, 2021, 72, 20-29.	0.2	3
133	Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. Nephrology Dialysis Transplantation, 2022, 37, 1868-1878.	0.4	43
135	Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. Journal of Clinical Virology, 2021, 145, 105026.	1.6	29
136	Coronavirus Disease 2019 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida Through August 2021. Clinical Infectious Diseases, 2022, 75, e892-e894.	2.9	25
137	BNT162b2 vaccination induces durable SARS-CoV-2â€“specific T cells with a stem cell memory phenotype. Science Immunology, 2021, 6, eabl5344.	5.6	166
138	Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nature Communications, 2021, 12, 6379.	5.8	214
139	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood, 2022, 139, 1588-1592.	0.6	70
140	Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5Âmonths after vaccination. Clinical and Experimental Medicine, 2022, 22, 477-485.	1.9	18
141	Gut microbiome, Vitamin D, ACE2 interactions are critical factors in immune-senescence and inflammaging: key for vaccine response and severity of COVID-19 infection. Inflammation Research, 2022, 71, 13-26.	1.6	10
142	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. Pathogens and Immunity, 2021, 6, 27-49.	1.4	10
143	Stress of Overseas Long-Distance Care During COVID-19: Potential "CALM"ing Strategies. Frontiers in Psychiatry, 2021, 12, 734967.	1.3	1
144	Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2â€“Naive Residents of Nursing Homes. Clinical Infectious Diseases, 2022, 75, e695-e704.	2.9	23
145	Post-vaccination SARS-CoV-2 infection among healthcare workers in tertiary care hospitals in Saudi Arabia: A case series. Journal of Infection and Public Health, 2022, 15, 10-12.	1.9	8
146	Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2. Clinica Chimica Acta, 2022, 524, 11-17.	0.5	16

#	Article	IF	Citations
147	Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in TucumÃ¡n, Argentina. The Lancet Regional Health Americas, 2022, 6, 100123.	1.5	21
148	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. Pathogens and Immunity, 2021, 6, 27-49.	1.4	46
149	Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls. American Journal of Gastroenterology, 2022, 117, 176-179.	0.2	36
150	Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infectious Diseases of Poverty, 2021, 10, 132.	1.5	244
151	Family matters for coronavirus disease and vaccines. Journal of Clinical Investigation, 2021, 131, .	3.9	2
152	Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatology, The, 2022, 4, e42-e52.	2.2	66
153	Do vaccines protect against long COVID? What the data say. Nature, 2021, 599, 546-548.	13.7	47
155	SARS-CoV-2: Overview and Its Impact on Oral Health. Biomedicines, 2021, 9, 1690.	1.4	7
156	An ethical analysis of vaccinating children against COVID-19: benefits, risks, and issues of global health equity. Wellcome Open Research, 0, 6, 252.	0.9	2
158	When Do We Need Massive Computations to Perform Detailed COVIDâ€19 Simulations?. Advanced Theory and Simulations, 2022, 5, 2100343.	1.3	8
159	Acceptance of the COVID-19 Vaccine by Foreigners in South Korea. International Journal of Environmental Research and Public Health, 2021, 18, 12035.	1.2	6
160	Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?. Molecular Biomedicine, 2021, 2, 38.	1.7	19
161	Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. Journal of Infectious Diseases, 2022, 225, 598-602.	1.9	40
163	A General Computational Framework for COVID-19 Modelling with Applications to Testing Varied Interventions in Education Environments. Covid, 2021, 1, 674-703.	0.7	2
165	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. Journal of Thoracic Oncology, 2022, 17, 214-227.	0.5	26
166	COVID-19 Survival and its impact on chronic kidney disease. Translational Research, 2022, 241, 70-82.	2.2	22
167	Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe. Journal of Clinical Medicine, 2021, 10, 5338.	1.0	30
170	Diagnostic Performance of Automated SARS-CoV-2 Antigen Assay in Nasal Swab during COVID-19 Vaccination Campaign. Diagnostics, 2021, 11, 2110.	1.3	6

#	Article	IF	Citations
173	Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience. Journal of Infectious Diseases, 2022, 225, 785-792.	1.9	38
175	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1013-1016.	0.5	43
176	mRNA vaccines against COVIDâ€19: a showcase for the importance of microbial biotechnology. Microbial Biotechnology, 2022, 15, 135-148.	2.0	9
177	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-Î± inhibitors. Med, 2021, 2, 1327-1341.e4.	2.2	31
178	Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay. Journal of Infection and Chemotherapy, 2022, 28, 273-278.	0.8	19
179	Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin. Virulence, 2021, 12, 2946-2956.	1.8	12
180	Comparison of long-term antibody response to mRNA SARS-CoV-2 vaccine among peritoneal dialysis and hemodialysis patients. Nephrology Dialysis Transplantation, 2022, 37, 602-604.	0.4	5
182	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Research, 2021, 81, 6273-6280.	0.4	30
183	Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects. Viruses, 2021, 13, 2329.	1.5	13
184	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 793953.	2.2	25
186	Higher frequency of comorbidities in fully vaccinated patients admitted to the ICU due to severe COVID-19: a prospective, multicentre, observational study. European Respiratory Journal, 2022, 59, 2102275.	3.1	23
187	Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas. American Journal of Pathology, 2022, 192, 320-331.	1.9	90
188	Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood, 2022, 139, 678-685.	0.6	96
190	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell, 2022, 185, 113-130.e15.	13.5	64
191	Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19. Medical Science Monitor, 2021, 27, e935624.	0.5	3
192	Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls. American Journal of Transplantation, 2022, 22, 1245-1252.	2.6	13
194	Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. Lancet Microbe, The, 2022, 3, e4-e5.	3.4	45
195	Effectiveness of ChAdOx1 nCOV-19 Vaccine: Experience of a tertiary care institute. Medical Journal Armed Forces India, 2021, 78, 117-117.	0.3	0

#	Article	IF	Citations
196	Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials. Translational and Regulatory Sciences, 2021, 3, 85-88.	0.2	0
197	Persistent B-Cell Memory After SARS-CoV-2 Vaccination is Functional During Breakthrough Infections. SSRN Electronic Journal, 0, , .	0.4	0
198	Waning of Serum Antibodies, But Increase of Protective B-Cell Memory Nine Months After BNT162b2 Vaccination. SSRN Electronic Journal, 0, , .	0.4	0
199	Covid-19 Infections in Vaccinated Health Care Workers. New England Journal of Medicine, 2022, 386, 193-193.	13.9	1
200	Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G. Internal Medicine, 2022, 61, 811-819.	0.3	6
201	Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. Nature Microbiology, 2022, 7, 277-288.	5.9	37
202	OUP accepted manuscript. Clinical Chemistry, 2022, , .	1.5	12
205	Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. Journal of Autoimmunity, 2022, 127, 102792.	3.0	96
206	Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. European Journal of Cancer, 2022, 162, 182-193.	1.3	40
207	Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody. Biosensors and Bioelectronics, 2022, 199, 113883.	5.3	21
208	International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation. Profilakticheskaya Meditsina, 2021, 24, 31.	0.2	1
210	SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review. Tropical Medicine and Infectious Disease, 2022, 7, 9.	0.9	14
212	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Science Translational Medicine, 2022, 14, eabl8124.	5.8	143
213	Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study. Vaccine, 2022, 40, 1082-1089.	1.7	9
214	Serological Markers of SARS-CoV-2 Reinfection. MBio, 2022, 13, e0214121.	1.8	8
215	Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. Cell Host and Microbe, 2022, 30, 400-408.e4.	5.1	75
216	SARS-CoV-2 Vaccines: Safety and Immunogenicity in Solid Organ Transplant Recipients and Strategies for Improving Vaccine Responses. Current Transplantation Reports, 2022, 9, 35-47.	0.9	13
217	Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. Journal of Hematology and Oncology, 2022, 15, 5.	6.9	30

#	Article	IF	Citations
218	Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women. Vaccines, 2022, 10, 101.	2.1	23
219	Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose. Vaccines, 2022, 10, 153.	2.1	20
220	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192.	6.0	91
221	<scp>COVID</scp>â€19 vaccine response in patients with hematologic malignancy: A systematic review and metaâ€analysis. American Journal of Hematology, 2022, 97, .	2.0	18
224	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity, 2022, 55, 355-365.e4.	6.6	76
225	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2022, 375, 43-50.	6.0	788
226	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
227	COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. Blood Reviews, 2022, 54, 100931.	2.8	49
228	Humoral responses to SARS-CoV-2 vaccination in rituximab-treated patients depend on peripheral B cell re-population rather than the timings of the dosing. Indian Journal of Rheumatology, 2022, 17, 30.	0.2	0
229	Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations. Pathogens, 2022, 11, 171.	1.2	4
230	A fatal case of COVIDâ€19 breakthrough infection due to the delta variant. Clinical Case Reports (discontinued), 2022, 10, e05232.	0.2	3
231	SARS-CoV-2 Variants, Vaccines, and Host Immunity. Frontiers in Immunology, 2021, 12, 809244.	2.2	176
232	Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine. Vaccines, 2022, 10, 177.	2.1	3
233	SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household. Journal of Korean Medical Science, 2022, 37, e12.	1.1	18
234	A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 1253-1260.	2.6	73
235	Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2. Frontiers in Immunology, 2022, 13, 811020.	2.2	11
236	Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico. Viruses, 2022, 14, 154.	1.5	7
237	Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients. Frontiers in Immunology, 2021, 12, 798389.	2.2	6

#	Article	IF	Citations
238	Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. Journal of Neuro-Oncology, 2022, 156, 483-489.	1.4	5
239	The Effect of COVID-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran. Iranian Journal of Public Health, 2022, 51, 188-195.	0.3	1
240	An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward. Journal of Korean Medical Science, 2022, 37, e28.	1.1	5
241	Why do parents willingness-to-pay to vaccinate their children against COVID-19? A real-world evidence in Taizhou, China. Human Vaccines and Immunotherapeutics, 2022, 18, 1-9.	1.4	6
242	Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses. PLoS ONE, 2022, 17, e0262657.	1.1	11
244	Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine, 2022, 40, 306-315.	1.7	107
245	Anti-SARS-CoV-2 Efficacy of Elaeocarpus sylvestris Extract Verified by in silico, in vitro, Preclinical, and Clinical Studies. SSRN Electronic Journal, 0, , .	0.4	0
246	Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical Conditions. Chest, 2022, 161, 1490-1493.	0.4	8
247	Effectiveness of Homologous and Heterologous Booster Shots for an Inactivated SARS-CoV-2 Vaccine: A Large-Scale Observational Study. SSRN Electronic Journal, 0, , .	0.4	8
248	Rapid antigen testing as a reactive response to surges in nosocomial SARS-CoV-2 outbreak risk. Nature Communications, 2022, 13, 236.	5.8	15
249	Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12Âweeks in South Korea: A prospective longitudinal study. Vaccine, 2022, 40, 437-443.	1.7	5
250	B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses. Emerging Microbes and Infections, 2022, 11, 452-464.	3.0	8
251	The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. Vaccines, 2022, 10, 140.	2.1	7
252	Evaluating immunity to <scp>SARSâ€CoV</scp>â€2 in nursing home residents using saliva <scp>IgG</scp>. Journal of the American Geriatrics Society, 2022, 70, 659-668.	1.3	7
253	Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model. Emerging Microbes and Infections, 2022, 11, 368-383.	3.0	33
254	Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality. Biology, 2022, 11, 177.	1.3	5
255	The next major emergent infectious disease: reflections on vaccine emergency development strategies. Expert Review of Vaccines, 2022, 21, 471-481.	2.0	9
256	Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies. Nephrology Dialysis Transplantation, 2022, 37, 1132-1139.	0.4	12

#	Article	IF	Citations
257	Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine, 2022, 75, 103788.	2.7	149
258	Adjudicating the logistics of COVID-19 vaccine boosters from a global perspective. Human Vaccines and Immunotherapeutics, 2022, , 1-3.	1.4	3
261	Decreased memory B cell frequencies in COVIDâ€19 delta variant vaccine breakthrough infection. EMBO Molecular Medicine, 2022, 14, e15227.	3.3	31
262	Finger stick blood test to assess postvaccination <scp>SARSâ€CoV</scp>â€2 neutralizing antibody response against variants. Bioengineering and Translational Medicine, 2022, 7, .	3.9	7
263	Transmissibility of SARS-CoV-2 among fully vaccinated individuals. Lancet Infectious Diseases, The, 2022, 22, 16.	4.6	32
264	Coronavirus Disease 2019 Messenger RNA Vaccines Associated With Delayed Onset of Breakthrough Infections and Fewer Radiographic Abnormalities. Clinical Infectious Diseases, 2022, 75, e905-e908.	2.9	5
267	Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA - Journal of the American Medical Association, 2022, 327, 341.	3.8	76
269	Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021. Frontiers in Medicine, 2021, 8, 815870.	1.2	8
272	COVID-19 mRNA vaccine safety, immunogenicity, and effectiveness in a hospital setting: confronting the challenge. Internal and Emergency Medicine, 2022, 17, 325-327.	1.0	3
273	Characteristics of Reported Deaths Among Fully Vaccinated Persons With Coronavirus Disease 2019â€"United States, Januaryâ€"April 2021. Clinical Infectious Diseases, 2022, 75, e645-e652.	2.9	9
274	Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 Outcomes â€" A Retrospective Cohort Study â€‹. SSRN Electronic Journal, 0, , .	0.4	0
275	COVID-19 reinfections among naturally infected and vaccinated individuals. Scientific Reports, 2022, 12, 1438.	1.6	79
277	Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. American Journal of Epidemiology, 2022, 191, 800-811.	1.6	53
278	SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. Frontiers in Immunology, 2022, 13, 825256.	2.2	54
279	Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Science Immunology, 2022, 7, eabn8014.	5.6	220
280	Neutralizing antibody activity against the B.1.617.2 (delta) variant 8Âmonths after two-dose vaccination with BNT162b2 in health care workers. Clinical Microbiology and Infection, 2022, 28, 1024.e7-1024.e12.	2.8	15
281	Imaging and Clinical Features of COVID-19 Breakthrough Infections: A Multicenter Study. Radiology, 2022, 303, 682-692.	3.6	44
282	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). Scientific Reports, 2022, 12, 1727.	1.6	11

#	Article	IF	Citations
283	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell, 2022, 185, 1008-1024.e15.	13.5	101
285	SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 â€“ April 2021. American Journal of Emergency Medicine, 2022, 54, 81-86.	0.7	3
286	Breakthrough COVID-19 Infections: What Are They and What Do They Look Like?. Radiology: Cardiothoracic Imaging, 2022, 4, .	0.9	1
287	Genomic, immunological, and clinical analysis of COVIDâ€19 vaccine breakthrough infections in Beijing, China. Journal of Medical Virology, 2022, 94, 2237-2249.	2.5	13
288	Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. Science Translational Medicine, 2022, 14, eabl6141.	5.8	52
289	COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrology Dialysis Transplantation, 2022, 37, 1357-1365.	0.4	17
290	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. Infection and Drug Resistance, 2022, Volume 15, 373-385.	1.1	24
291	SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study. Journal of Infectious Diseases, 2022, , .	1.9	6
292	WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. Lancet Microbe, The, 2022, 3, e81-e82.	3.4	56
293	Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study. Infectious Diseases Now, 2022, 52, 40-43.	0.7	5
294	Immunity to SARS-CoV-2 up to 15Âmonths after infection. IScience, 2022, 25, 103743.	1.9	56
295	COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose. Journal of the Neurological Sciences, 2022, 434, 120155.	0.3	49
296	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight, 2022, 7, .	2.3	12
297	Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe, The, 2022, 3, e274-e283.	3.4	51
299	SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies. Journal of Clinical Investigation, 2022, 132, .	3.9	30
301	Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients. Clinical and Experimental Nephrology, 2022, 26, 571-580.	0.7	13
302	Development of a TÂcell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status. Cell Host and Microbe, 2022, 30, 388-399.e3.	5.1	26
303	Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail Population. Vaccines, 2022, 10, 260.	2.1	14

#	Article	IF	Citations
305	Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 403-413.	2.2	43
306	A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity. Journal of Infection and Chemotherapy, 2022, 28, 962-964.	0.8	1
308	Advanced Liver Fibrosis Correlates With Impaired Efficacy of Pfizerâ€BioNTech COVIDâ€19 Vaccine in Medical Employees. Hepatology Communications, 2022, 6, 1278-1288.	2.0	4
309	Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy). Viruses, 2022, 14, 336.	1.5	29
310	Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2. Frontiers in Medicine, 2022, 9, 811004.	1.2	3
311	A Mathematical Study of COVID-19 Spread by Vaccination Status in Virginia. Applied Sciences (Switzerland), 2022, 12, 1723.	1.3	5
314	Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. Journal of Hematology and Oncology, 2022, 15, 15.	6.9	21
315	SARS-CoV-2 antibody testing for transplant recipients: A tool to personalize protection versus COVID-19. American Journal of Transplantation, 2022, 22, 1316-1320.	2.6	18
316	Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs. Vaccines, 2022, 10, 252.	2.1	12
317	Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115659.	0.8	44
318	Growing Understanding of the Clinical and Serologic Effects of COVID-19 Vaccines in Patients Undergoing Long-Term Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, , CJN.00320122.	2.2	1
319	A Reinforcement Learning Based Decision Support Tool for Epidemic Control: Validation Study for COVID-19. Applied Artificial Intelligence, 2022, 36, .	2.0	3
320	Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort. Annals of the Rheumatic Diseases, 2022, 81, 868-874.	0.5	57
321	Post-Vaccination SARS-CoV-2 Infections among Health Workers at the University Hospital of Verona, Italy: A Retrospective Cohort Survey. Vaccines, 2022, 10, 272.	2.1	24
322	Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection. JAMA - Journal of the American Medical Association, 2022, 327, 179.	3.8	89
323	Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy. JAMA Pediatrics, 2022, 176, 290.	3.3	53
324	Contact tracing as a measure to combat COVID-19 and other infectious diseases. American Journal of Infection Control, 2022, 50, 638-644.	1.1	9
325	Diagnostics for COVID-19: moving from pandemic response to control. Lancet, The, 2022, 399, 757-768.	6.3	230

#	Article	IF	Citations
326	Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatology, The, 2022, 4, e177-e187.	2.2	122
327	The germinal centre B cell response to SARS-CoV-2. Nature Reviews Immunology, 2022, 22, 7-18.	10.6	150
328	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nature Reviews Immunology, 2022, 22, 57-65.	10.6	217
329	Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China. Expert Review of Vaccines, 2022, 21, 261-267.	2.0	40
330	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. Clinical and Experimental Immunology, 2022, 207, 263-271.	1.1	14
331	Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study. Clinical Infectious Diseases, 2022, 75, e683-e691.	2.9	48
332	Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19â€“Convalescent Individuals. Journal of Infectious Diseases, 2022, 225, 1905-1908.	1.9	14
337	Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD Open, 2021, 7, e002008.	1.8	28
338	Chest Radiographic and CT Findings in Patients Hospitalized with Breakthrough COVID-19. Radiology: Cardiothoracic Imaging, 2021, 3, e210248.	0.9	4
339	SARS-CoV-2â€“neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma. Blood Advances, 2022, 6, 1580-1584.	2.5	8
340	Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines. Frontiers in Medicine, 2021, 8, 778129.	1.2	30
341	Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months. Vaccines, 2021, 9, 1500.	2.1	22
342	SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis. Annals of Internal Medicine, 2022, 175, 371-378.	2.0	55
344	Interim statement on covid-19 vaccine booster doses. Neurosciences, 2021, 26, 403-405.	0.1	2
345	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021, , eab3435.	6.0	145
346	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2021, , eabm0811.	6.0	10
348	Kinetics and Factors Associated With 12-Month Persistence of Neutralizing Antibody Induced by Two Inactivated COVID-19 Vaccines. SSRN Electronic Journal, 0, , .	0.4	0
349	Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic. Journal of Korean Medical Science, 2022, 37, e67.	1.1	3

#	Article	IF	Citations
350	Large inter-individual variability of cellular and humoral immunological responses to mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in health care workers. Clinical and Experimental Vaccine Research, 2022, 11, 96.	1.1	3
351	Prevalence, characteristics, and predictors of healthcare workers with COVID-19 infection in an urban district in Malaysia. Pan African Medical Journal, 0, 41, .	0.3	3
352	Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers. Infection and Chemotherapy, 2022, 54, 140.	1.0	4
353	Serological Screening of Immunoglobulin G against SARS-CoV-2 Nucleocapsid and Spike Protein before and after Two Vaccine Doses among Healthcare Workers in Japan. Tohoku Journal of Experimental Medicine, 2022, , .	0.5	2
354	Factors Associated with Change in SARS-CoV-2 Antibody Titers from Three to Six Months after the Administration of the BNT162b2 mRNA COVID-19 Vaccine among Healthcare Workers in Japan: A Prospective Study. Internal Medicine, 2022, 61, 1139-1143.	0.3	7
355	Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients. American Journal of Nephrology, 2022, 53, 207-214.	1.4	19
356	Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. Cell Discovery, 2022, 8, 17.	3.1	23
357	Vaccination provides protection from respiratory deterioration and death among hospitalized COVIDâ€19 patients: Differences between vector and mRNA vaccines. Journal of Medical Virology, 2022, 94, 2849-2854.	2.5	19
358	Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccineâ€“A Study Protocol. Frontiers in Medicine, 2022, 9, 761655.	1.2	4
359	Integrated model for COVID-19 diagnosis based on computed tomography artificial intelligence, and clinical features: a multicenter cohort study. Annals of Translational Medicine, 2022, 10, 130-130.	0.7	3
361	Mitigating SARS-CoV-2 Transmission in Hospitals: A Systematic Literature Review. Public Health Reviews, 2022, 43, 1604572.	1.3	8
362	Respiratory Mucosal Immunity: Kinetics of Secretory Immunoglobulin A in Sputum and Throat Swabs From COVID-19 Patients and Vaccine Recipients. Frontiers in Microbiology, 2022, 13, 782421.	1.5	8
363	Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients. Journal of Nephrology, 2022, 35, 1479-1487.	0.9	18
364	Getting infected with SARS-CoV-2. International Journal of Therapy and Rehabilitation, 2022, 29, 1-4.	0.1	0
365	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discovery, 2022, 12, 958-983.	7.7	10
367	COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. Kidney International, 2022, 101, 883-894.	2.6	82
368	Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients. Kidney International Reports, 2022, 7, 1103-1107.	0.4	8
369	The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. Clinical Microbiology and Infection, 2022, 28, 735.e5-735.e8.	2.8	12

#	Article	IF	Citations
370	The Effect of Gestational Age at BNT162b2 mRNA Vaccination on Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Levels. Clinical Infectious Diseases, 2022, 75, e603-e610.	2.9	27
371	Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizerâ€"BioNTech) in Patients on Hemodialysis. Vaccines, 2022, 10, 327.	2.1	7
372	Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents. Journal of the American Medical Directors Association, 2022, 23, 750-753.	1.2	11
373	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Scientific Reports, 2022, 12, 2628.	1.6	34
374	Antibody titers after SARSâ€CoVâ€2 mRNA vaccination in patients with aplastic anemiaâ€"A singleâ€center study. European Journal of Haematology, 2022, 108, 528-531.	1.1	4
375	Effectiveness of a novel semiâ€closed barrier device with a personalized exhaust in cough aerosol simulation according to particle counts and visualization of particles. Indoor Air, 2022, 32, e12988.	2.0	4
376	Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers. Human Vaccines and Immunotherapeutics, 2022, 18, 1-5.	1.4	7
377	The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study. Microbiology Spectrum, 2022, 10, e0140221.	1.2	20
378	Spotlight in Plastic Surgery: April 2022. Plastic and Reconstructive Surgery, 2022, 149, 1027-1029.	0.7	0
380	Trained Immunity: An Overview and the Impact on COVID-19. Frontiers in Immunology, 2022, 13, 837524.	2.2	35
381	Strategies to successfully prevent COVID-19 outbreak in vulnerable uro-oncology patient population. Infection, 2022, , 1.	2.3	1
383	Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors. Vaccines, 2022, 10, 366.	2.1	39
384	Levels, Predictors, and Distribution of Interpersonal Solidarity during the COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 2022, 19, 2041.	1.2	5
386	Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern. Signal Transduction and Targeted Therapy, 2022, 7, 61.	7.1	12
387	Taiwan's Response to Influenza: A Seroepidemiological Evaluation of Policies and Implications for Pandemic Preparedness. International Journal of Infectious Diseases, 2022, , .	1.5	0
388	COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience. Leukemia and Lymphoma, 2022, 63, 1723-1727.	0.6	1
390	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine, 2022, 28, 1072-1082.	15.2	147
391	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. Vaccines, 2022, 10, 285.	2.1	13

#	Article	IF	Citations
392	Knowledge, Attitude, and Practice (KAP) toward COVID-19 Pandemic among the Public in Taiwan: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 2784.	1.2	14
393	High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens. Microbiology Spectrum, 2022, 10, e0169521.	1.2	8
394	Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nature Communications, 2022, 13, 1614.	5.8	117
395	Low antispike antibody levels correlate with poor outcomes in COVIDâ€19 breakthrough hospitalizations. Journal of Internal Medicine, 2022, 292, 127-135.	2.7	15
396	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. Human Vaccines and Immunotherapeutics, 2022, 18, 2040330.	1.4	5
397	The Current Knowns and Unknowns of COVID-19 Vaccine-Induced Immunity in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2022, 117, 731-732.	0.2	0
399	Communication about vaccine efficacy and COVID-19 vaccine choice: Evidence from a survey experiment in the United States. PLoS ONE, 2022, 17, e0265011.	1.1	4
400	Global Trends and Research Hotspots in Long COVID: A Bibliometric Analysis. International Journal of Environmental Research and Public Health, 2022, 19, 3742.	1.2	11
402	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature Reviews Clinical Oncology, 2022, 19, 385-401.	12.5	135
403	COVID-19 Infection in Vaccinated Healthcare Professionals. Cureus, 2022, 14, e23386.	0.2	1
404	The (apparent) antibody paradox in COVID-19. Expert Review of Clinical Immunology, 2022, 18, 335-345.	1.3	9
405	Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?. Frontiers in Microbiology, 2022, 13, 763169.	1.5	3
406	Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. Frontiers in Immunology, 2022, 13, 861050.	2.2	8
407	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. Frontiers in Drug Discovery, 2022, 2, .	1.1	4
408	Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?. Journal of Clinical Microbiology, 2022, 60, e0048221.	1.8	21
409	Long COVID: A growing problem in need of intervention. Cell Reports Medicine, 2022, 3, 100552.	3.3	16
410	An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy. Scientific Reports, 2022, 12, 3794.	1.6	14
411	The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. Clinical Chemistry and Laboratory Medicine, 2022, 60, 934-940.	1.4	5

#	Article	IF	Citations
413	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases, 2022, 9, ofac124.	0.4	25
414	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. ACS Infectious Diseases, 2022, 8, 825-840.	1.8	3
416	Posterior Pharyngeal Follicles in a Woman with Breakthrough SARS-CoV-2 Infection. American Journal of Tropical Medicine and Hygiene, 2022, , .	0.6	1
417	Establishment of an inâ€house realâ€time RTâ€PCR assay for the detection of severe acute respiratory syndrome coronavirus 2 using the first World Health Organization international standard in a resourceâ€limited country. Journal of Clinical Laboratory Analysis, 2022, 36, e24355.	0.9	2
418	The Effect of COVID-19 Endemicity on the Mental Health of Health Workers. Journal of the American Medical Directors Association, 2022, 23, 405-413.e3.	1.2	15
419	Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients. Transplantation Proceedings, 2022, 54, 1439-1445.	0.3	8
420	Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose. Frontiers in Public Health, 2022, 10, 847384.	1.3	12
421	SARS-CoV-2 variants, immune escape, and countermeasures. Frontiers of Medicine, 2022, 16, 196-207.	1.5	39
422	Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection. Vaccines, 2022, 10, 502.	2.1	12
423	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell, 2022, 185, 1556-1571.e18.	13.5	179
424	Neutralizing antibodies to SARSâ€CoVâ€2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. European Journal of Immunology, 2022, 52, 816-824.	1.6	31
425	Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility. Vaccines, 2022, 10, 446.	2.1	7
426	Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. Rheumatology, 2022, 61, 4482-4490.	0.9	14
427	Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life, 2022, 12, 453.	1.1	12
428	Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. International Journal of Infectious Diseases, 2022, 119, 87-94.	1.5	35
430	Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers. Journal of Infection and Chemotherapy, 2022, 28, 802-805.	0.8	18
431	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. JAMA Oncology, 2022, 8, e220446.	3.4	48
432	Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination. Vaccines, 2022, 10, 451.	2.1	6

#	Article	IF	Citations
433	Higher vaccination rates predict reduction in SARS-CoV-2 transmission across the United States. Infection, 2022, 50, 1255-1266.	2.3	6
434	Characterization of the significant decline in humoral immune response six months postâ€SARSâ€CoVâ€2 mRNA vaccination: A systematic review. Journal of Medical Virology, 2022, 94, 2939-2961.	2.5	89
435	Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. Journal of Medical Virology, 2022, 94, 3416-3420.	2.5	41
436	RapidQ: A reader-free microfluidic platform for the quantitation of antibodies against the SARS-CoV-2 spike protein. Biomicrofluidics, 2022, 16, 024105.	1.2	2
437	Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. Microbiology Spectrum, 2022, 10, e0270221.	1.2	3
438	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. Frontiers in Immunology, 2022, 13, 773982.	2.2	10
439	Utilization of SARS-COV-2 positive donors and recipients for Liver transplantation in the pandemic era â€“ An evidence-based review. Journal of Liver Transplantation, 2022, , 100081.	0.2	2
440	Manifesto of the pediatricians of Emilia-Romagna region, Italy, in favor of vaccination against COVID in children 5â€“11Âyears old. Italian Journal of Pediatrics, 2022, 48, 40.	1.0	5
441	COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron. Vaccines, 2022, 10, 391.	2.1	15
442	Postâ€“COVID-19 syndrome and humoral response association after 1Âyear in vaccinated and unvaccinated patients. Clinical Microbiology and Infection, 2022, 28, 1140-1148.	2.8	35
443	Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring. Microbiology Spectrum, 2022, 10, e0039622.	1.2	6
446	Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?. Vaccine, 2022, 40, 2251-2257.	1.7	32
447	Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. Journal of Infection and Chemotherapy, 2022, 28, 1015-1017.	0.8	7
448	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	2.3	26
449	Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV. Emerging Microbes and Infections, 2022, 11, 1126-1134.	3.0	37
450	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	1.9	3
451	High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge. Nature Communications, 2022, 13, 1726.	5.8	5
452	Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 1781-1786.	0.9	19

#	Article	IF	Citations
453	The impact of COVIDâ€19 on the patient, clinician, healthcare services and society: A patient pathway review. Journal of Medical Virology, 2022, , .	2.5	7
455	Boosters reduce in-hospital mortality in patients with COVID-19: An observational cohort analysis. The Lancet Regional Health Americas, 2022, 8, 100227.	1.5	8
456	Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. Clinical Immunology, 2022, 238, 108999.	1.4	10
457	Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021. JAMA Oncology, 2022, 8, 1027.	3.4	61
458	In-depth analysis of SARS-CoV-2â€“specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight, 2022, 7, .	2.3	9
459	Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia. Journal of Infection and Public Health, 2022, 15, 573-577.	1.9	7
460	Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVIDâ€19 Trial of Nirmatrelvir. Clinical Pharmacology and Therapeutics, 2022, 112, 101-111.	2.3	76
461	The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets. Kidney International Supplements, 2022, 12, 48-62.	4.6	10
462	The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-Î³ release by natural killer cells. Vaccine, 2022, 40, 2619-2625.	1.7	6
463	Longâ€term effects of <scp>SARSâ€CoV</scp>â€2 vaccination in the nursing home setting. Journal of the American Geriatrics Society, 2022, 70, 1336-1341.	1.3	7
464	Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. New England Journal of Medicine, 2022, 386, 1377-1380.	13.9	332
465	Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS ONE, 2022, 17, e0266852.	1.1	49
466	Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients. Scientific Reports, 2022, 12, 5876.	1.6	12
467	Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia. International Journal of Molecular Sciences, 2022, 23, 4062.	1.8	8
468	SARS-CoV-2â€“specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. JCI Insight, 2022, 7, .	2.3	15
469	SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. International Journal of Infectious Diseases, 2022, 118, 95-103.	1.5	24
470	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. EBioMedicine, 2022, 79, 103986.	2.7	23
471	Trajectory of SARS-CoV-2 anti-S IgG levels following transfusion and a third dose of BNT162b2 vaccine in a patient with massive postoperative bleeding: A case report. International Journal of Infectious Diseases, 2022, 118, 138-140.	1.5	0

#	Article	IF	Citations
472	Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection. International Journal of Infectious Diseases, 2022, 119, 18-20.	1.5	0
474	Protection from covid-19 at work: health and safety law is fit for purpose. BMJ, The, 2021, 375, n3087.	3.0	4
475	ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants. Endoscopy, 2022, 54, 211-216.	1.0	12
477	RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor. Viruses, 2022, 14, 1.	1.5	23
478	A Narrative Review of COVID-19 Vaccines. Vaccines, 2022, 10, 62.	2.1	40
480	Trends in COVID-19 Health Disparities in North Carolina: Preparing the Field for Long-Haul Patients. Healthcare (Switzerland), 2021, 9, 1704.	1.0	1
481	Modeling the Influence of Vaccine Administration on COVID-19 Testing Strategies. Viruses, 2021, 13, 2546.	1.5	7
483	Criteria for judging the immune markers of COVIDâ€19 disease vaccines. MedComm, 2022, 3, 1-12.	3.1	3
486	Why do breakthrough COVID-19 infections occur in the vaccinated?. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 67-68.	0.2	2
490	Time course of antibody concentrations against the spike protein of SARSâ€CoVâ€2 among healthy hospital workers up to 200 days after their first COVIDâ€19 vaccination. Journal of Clinical Laboratory Analysis, 2022, 36, e24175.	0.9	4
493	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discovery, 2022, 12, 303-330.	7.7	24
494	Global implication of booster doses of COVID-19 vaccine. Infezioni in Medicina, 2021, 29, 643-647.	0.7	2
495	Boosting Vaccine-Elicited Respiratory Mucosal and Systemic COVID-19 Immunity in Mice With the Oral Lactobacillus plantarum. Frontiers in Nutrition, 2021, 8, 789242.	1.6	23
496	Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 98-106.	2.2	22
497	Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study. Expert Review of Anti-Infective Therapy, 2022, 20, 781-787.	2.0	2
498	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. Journal of Microbiology and Biotechnology, 2021, 31, 1601-1614.	0.9	8
502	Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy. Infectious Diseases and Therapy, 2022, 11, 607-615.	1.8	0
503	Mediating Effect of Viral Anxiety and Perceived Benefits of Physical Distancing on Adherence to Distancing Among High School Students Amid COVID-19. Journal of Korean Medical Science, 2022, 37, e129.	1.1	2

#	Article	IF	Citations
504	Impact of SARSâ€CoVâ€2 infection on vaccineâ€induced immune responses over time. Clinical and Translational Immunology, 2022, 11, e1388.	1.7	20
505	Vaccination and Covid 19 Infections. Medicina Interna (Bucharest, Romania: 1991), 2022, 19, 97-105.	0.1	0
506	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Science Translational Medicine, 2022, 14, eabm2311.	5.8	100
507	Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib. Frontiers in Medicine, 2022, 9, 826537.	1.2	5
508	Humoral immunity in dually vaccinated SARS-CoV-2-naÃ¯ve individuals and in booster-vaccinated COVID-19-convalescent subjects. Infection, 2022, , 1.	2.3	11
509	Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands. Npj Digital Medicine, 2022, 5, 49.	5.7	24
510	SARSâ€CoVâ€2 Deltaâ€variant breakthrough infections in nursing home residents at midterm after ComirnatyÂ® COVIDâ€19 vaccination. Journal of Medical Virology, 2022, 94, 3776-3782.	2.5	6
511	Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients. Clinical and Experimental Nephrology, 2022, 26, 925-932.	0.7	4
514	Risks of catching COVIDâ€19 according to vaccination status of healthcare workers during the SARSâ€CoVâ€2 Delta variant dominant period and their clinical characteristics. Journal of Medical Virology, 2022, 94, 3706-3713.	2.5	7
515	COVIDâ€19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. Alzheimer's and Dementia, 2023, 19, 421-432.	0.4	26
516	A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients. Journal of Hepatology, 2022, 77, 702-709.	1.8	35
517	COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia. Emerging Microbes and Infections, 2022, 11, 1262-1271.	3.0	21
518	Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection. Open Forum Infectious Diseases, 2022, 9, .	0.4	8
519	Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients. Vaccines, 2022, 10, 605.	2.1	5
520	SARS-CoV-2 Delta Variant in Jingmen City, Hubei Province, China, 2021: Children Susceptible and Vaccination Breakthrough Infection. Frontiers in Microbiology, 2022, 13, 856757.	1.5	10
521	Higher Antibody Concentrations in U.S. Health Care Workers Associated with Greater Reactogenicity Post-Vaccination. Vaccines, 2022, 10, 601.	2.1	7
522	Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology. Journal of Molecular Cell Biology, 2022, 14, .	1.5	4
523	Social cognition theories and behavior change in COVID-19: A conceptual review. Behaviour Research and Therapy, 2022, 154, 104095.	1.6	16

#	Article	IF	Citations
524	Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China. Infection and Drug Resistance, 2022, Volume 15, 2091-2100.	1.1	18
525	Intramuscular AZD7442 (Tixagevimabâ€“Cilgavimab) for Prevention of Covid-19. New England Journal of Medicine, 2022, 386, 2188-2200.	13.9	450
526	Immunogenicity and safety of COVID-19 vaccination in patients with primary SjÃ¶grenâ€™s syndrome. RMD Open, 2022, 8, e002265.	1.8	5
527	Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 66, 128732.	1.0	3
528	Stress of Overseas Long-Distance Care During COVID-19: Potential â€œCALMâ€ing Strategies. Frontiers in Psychiatry, 2021, 12, 734967.	1.3	2
529	Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant. JAMA Oncology, 2022, 8, 1053.	3.4	16
530	Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunology, 2022, 15, 799-808.	2.7	152
531	Impact of prior vaccination on clinical outcomes of patients with COVID-19. Emerging Microbes and Infections, 2022, 11, 1316-1324.	3.0	7
532	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open, 2022, 8, e002187.	1.8	34
533	Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster. Clinical Chemistry and Laboratory Medicine, 2022, 60, e153-e156.	1.4	7
534	BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients. Transplant International, 2022, 35, 10239.	0.8	17
535	Vaccine Breakthrough Infections of SARS-Cov-2: A Case Report.. Ethiopian Journal of Health Sciences, 2022, 32, 201-204.	0.2	0
536	Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA Vaccines. SSRN Electronic Journal, 0, , .	0.4	3
537	Humoral immunity against SARSâ€CoVâ€2 variants including omicron in solid organ transplant recipients after three doses of a COVIDâ€19 mRNA vaccine. Clinical and Translational Immunology, 2022, 11, e1391.	1.7	21
539	Variant-specific vaccination induces systems immune responses and potent inÂvivo protection against SARS-CoV-2. Cell Reports Medicine, 2022, 3, 100634.	3.3	10
540	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. Vaccines, 2022, 10, 695.	2.1	16
541	Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series. Frontiers in Public Health, 2022, 10, 875558.	1.3	3
542	The impact of vaccination against the new coronavirus infection on the morbidity of university students. Russian Family Doctor, 2022, 26, 21-26.	0.1	0

#	Article	IF	Citations
543	Assessment and Monitoring of Coagulation in Patients with COVID-19: A Review of Current Literature. Hamostaseologie, 2022, 42, 409-419.	0.9	3
544	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. Frontiers in Immunology, 2022, 13, 814365.	2.2	10
545	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatology, The, 2022, 4, e417-e429.	2.2	33
546	Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nature Communications, 2022, 13, 2318.	5.8	33
547	SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination. Microorganisms, 2022, 10, 857.	1.6	8
548	Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study. Tropical Medicine and Infectious Disease, 2022, 7, 66.	0.9	9
549	Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2. Vaccines, 2022, 10, 649.	2.1	6
550	A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. PLoS Pathogens, 2022, 18, e1010465.	2.1	8
551	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. Nature Reviews Immunology, 2022, 22, 387-397.	10.6	93
554	Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era. PLoS ONE, 2022, 17, e0268050.	1.1	19
555	Time-Dependent Increase in Susceptibility and Severity of Secondary Bacterial Infections During SARS-CoV-2. Frontiers in Immunology, 2022, 13, .	2.2	11
556	Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cellâ€“depleted lymphoma after CART therapy. Blood, 2022, 140, 152-156.	0.6	17
557	Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2. Expert Review of Clinical Immunology, 2022, 18, 557-565.	1.3	10
558	SARS-CoV-2 RT-qPCR testing of pooled saliva samples: A case study of 824 asymptomatic individuals and a questionnaire survey in Japan. PLoS ONE, 2022, 17, e0263700.	1.1	0
559	Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch. Frontiers in Virology, 2022, 2, .	0.7	14
560	Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients. Clinical and Molecular Hepatology, 2022, 28, 553-564.	4.5	9
561	Comparison of the Clinical and Laboratory Findings and Outcomes of Hospitalized COVID-19 Patients Who Were Either Fully Vaccinated with Coronavac or Not: An Analytical, Cross Sectional Study. Vaccines, 2022, 10, 733.	2.1	4
562	Analysis of contact tracing surveillance for COVID-19 among healthcare workers in secondary referral hospital, Indonesia. F1000Research, 0, 11, 506.	0.8	0

#	Article	IF	Citations
563	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology and Oncology, 2022, 15, 54.	6.9	26
564	Determinants of the willingness to get the third COVID-19 vaccine dose among health care workers. Infectious Diseases Now, 2022, 52, 223-226.	0.7	2
565	Quantification and progress over time of specific antibodies against SARS-CoV-2 in breast milk of lactating women vaccinated with BNT162b2 Pfizer-BioNTech COVID-19 vaccine (LacCOVID). Open Forum Infectious Diseases, 0, , .	0.4	2
566	Changes in Parental Attitudes Toward COVID-19 Vaccination and Routine Childhood Vaccination During the COVID-19 Pandemic: Repeated Cross-sectional Survey Study. JMIR Public Health and Surveillance, 2022, 8, e33235.	1.2	11
567	Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nature Immunology, 2022, 23, 940-946.	7.0	67
568	Incorporating economic constraints for optimal control of immunizing infections. Chaos, 2022, 32, 053101.	1.0	1
569	Trends and Correlates of Breakthrough Infections With SARS-CoV-2. Frontiers in Public Health, 2022, 10, .	1.3	5
570	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. Dr Sulaiman Al Habib Medical Journal, 0, , 1.	0.3	0
571	Antiâ€spike <scp>IgG</scp> antibody kinetics following the second and third doses of <scp>BNT162b2</scp> vaccine in nursing home residents. Journal of the American Geriatrics Society, 2022, 70, 2552-2560.	1.3	11
572	SARS-CoV-2 Infection Evolution Among Nephrologists During the Pandemic: Clinical Features and Impact of Vaccination. Kidney International Reports, 2022, 7, 1686-1689.	0.4	2
573	Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. Vaccines, 2022, 10, 755.	2.1	13
574	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine, 2022, 80, 104042.	2.7	54
575	Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. The Lancet Global Health, 2022, 10, e798-e806.	2.9	141
576	Clinical update on COVID-19 for the emergency clinician: Cardiac arrest in the out-of-hospital and in-hospital settings. American Journal of Emergency Medicine, 2022, 57, 114-123.	0.7	4
577	Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis. JMIR Public Health and Surveillance, 2022, 8, e35311.	1.2	13
578	The Impacts of Gradually Terminating Nonpharmaceutical Interventions for SARS-CoV-2: A Mathematical Modelling Analysis. Fundamental Research, 2022, , .	1.6	0
579	Breakthrough Infections of COVID-19 among Vaccinated Healthcare Workers in a Tertiary Care Hospital in Northern Kerala, India. Journal of Pure and Applied Microbiology, 0, , .	0.3	0
580	Demographic and Clinical Factors Associated With Antiâ€“SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses. JAMA Network Open, 2022, 5, e2212996.	2.8	9

#	Article	IF	Citations
581	COVID-19 in the Airline Industry: The Good, the Bad, and the Necessary. New Solutions, 2022, 32, 92-99.	0.6	3
584	Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. BMJ Open, 2022, 12, e059994.	0.8	17
585	A SARS-CoV-2 outbreak associated with vaccine breakthrough in an acute care hospital. American Journal of Infection Control, 2022, 50, 1006-1012.	1.1	3
586	Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine. Immunity and Ageing, 2022, 19, .	1.8	9
587	Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study. Journal of Hematology and Oncology, 2022, 15, .	6.9	9
588	Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respiratory Medicine,the, 2022, 10, 749-760.	5.2	65
589	ASSESSMENT OF THE HUMORAL IMMUNITY INDUCED BY SPUTNIK V COVID-19 VACCINE (GAM-COVID-VAC) IN HEALTHCARE WORKERS. Vacunas (English Edition), 2022, , .	0.3	0
590	Estimation of the Seroprevalence and Infection Fatality Rate of the SARS-CoV-2 Omicron Variant Using Antibody Screening of Danish Blood Donors. SSRN Electronic Journal, 0, , .	0.4	0
591	Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies. Frontiers in Neurology, 2022, 13, .	1.1	34
592	Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study. Vaccines, 2022, 10, 862.	2.1	5
593	How Should Anesthesiologists Face Coronavirus Disease 2019?. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	0
594	Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals. Frontiers in Immunology, 2022, 13, .	2.2	11
595	Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review. Tropical Medicine and Infectious Disease, 2022, 7, 81.	0.9	15
596	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. Medical Review, 2022, 2, 169-196.	0.3	5
597	Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore. Antibodies, 2022, 11, 38.	1.2	4
598	B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. Med, 2022, 3, 468-480.e5.	2.2	2
600	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nature Microbiology, 2022, 7, 896-908.	5.9	32
601	Comparison of Four Systems for SARS-CoV-2 Antibody at Three Time Points after SARS-CoV-2 Vaccination. Diagnostics, 2022, 12, 1349.	1.3	0

#	Article	IF	Citations
602	Outcome of liver cancer patients with SARSâ€CoVâ€2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	1.9	11
603	The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. Emerging Microbes and Infections, 2022, 11, 1524-1536.	3.0	39
604	The Provision of Dental Care to Post COVID-19 Survivors. A Concise Review. International Dental Journal, 2022, , .	1.0	1
605	Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain. Scientific Reports, 2022, 12, .	1.6	9
606	COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis. Clinical and Molecular Hepatology, 2022, 28, 890-911.	4.5	29
607	Correlates of protection against <scp>SARS</scp>â€<scp>CoV</scp>â€2 infection and COVIDâ€19 disease. Immunological Reviews, 2022, 310, 6-26.	2.8	138
608	Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	21
609	Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories. Nature Communications, 2022, 13, .	5.8	59
610	COVID-19 Vaccine Intention and Knowledge, Literacy, and Health Beliefs among Japanese University Students. Vaccines, 2022, 10, 893.	2.1	6
611	SERS-based assay for multiplexed detection of cross-reactivity and persistence of antibodies against the spike of the native, P.1 and B.1.617.2 SARS-CoV-2 in non-hospitalised adults. Sensors & Diagnostics, 2022, 1, 851-866.	1.9	3
612	Natural tannins as anti-SARS-CoV-2 compounds. International Journal of Biological Sciences, 2022, 18, 4669-4676.	2.6	18
613	Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trials. Indian Journal of Rheumatology, 2022, 17, 300.	0.2	2
614	Impact of ChAdOx1 nCoV-19 (Covishieldâ„¢) Vaccination: How Long Will It Persist?. International Journal of Microbiology, 2022, 2022, 1-7.	0.9	1
616	Back to the Future: Can Vaccines Win the Long-Term Fight Against COVID-19?. Frontiers in Public Health, 0, 10, .	1.3	1
617	Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V. International Journal of Infectious Diseases, 2022, 122, 850-854.	1.5	6
618	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology, 2023, 8, .	5.6	35
619	Risk of SARS-CoV-2 Infection Breakthrough among the Non-Vaccinated and Vaccinated Population in Italy: A Real-World Evidence Study Based on Big Data. Healthcare (Switzerland), 2022, 10, 1085.	1.0	1
620	Nomogram Model for Prediction of SARS-CoV-2 Breakthrough Infection in Fujian: A Caseâ€“Control Real-World Study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	2

#	Article	IF	Citations
621	SARS-CoV-2: A Master of Immune Evasion. Biomedicines, 2022, 10, 1339.	1.4	24
622	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. International Journal of Translational Medicine, 2022, 2, 275-308.	0.1	1
623	Understanding determinants of COVID-19 vaccine hesitancy; an emphasis on the role of religious affiliation and individualâ€™s reliance on traditional remedy. BMC Public Health, 2022, 22, .	1.2	10
624	Clinical Characteristics and Outcomes of Patients Hospitalized with COVID-19 at Case Hospital, Uganda. Interdisciplinary Perspectives on Infectious Diseases, 2022, 2022, 1-11.	0.6	5
625	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nature Medicine, 2022, 28, 1715-1722.	15.2	29
626	Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?. PLoS ONE, 2022, 17, e0263486.	1.1	0
627	Side Effects and Perceptions of COVID-19 Vaccination in Saudi Arabia: A Cross-Sectional Study. Frontiers in Medicine, 0, 9, .	1.2	5
629	IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. Frontiers in Immunology, 0, 13, .	2.2	16
630	Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine. Vaccine, 2022, 40, 4538-4543.	1.7	16
631	Positivity rates of SAR-CoV-2 infection in orthodontic patients at the orthodontic clinic, University of Illinois Chicago. PLoS ONE, 2022, 17, e0270311.	1.1	1
632	The role of precautions: Organising a medical conference during COVIDâ€19 pandemicâ€”Lessons from IADVL MIDDERMACON 2021. , 2022, 1, 264-267.		0
633	COVID-19 Vaccination Hesitancy among Healthcare Workersâ€”A Review. Vaccines, 2022, 10, 948.	2.1	88
635	Considerations regarding Interpretation of Positive SARS-CoV-2 Molecular Results with Late Cycle Threshold Values. Journal of Clinical Microbiology, 2022, 60, .	1.8	4
636	Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab. Vaccines, 2022, 10, 901.	2.1	13
638	Expert review on global real-world vaccine effectiveness against SARS-CoV-2. Expert Review of Vaccines, 2022, 21, 1255-1268.	2.0	30
639	COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins. Cell Reports, 2022, 40, 111022.	2.9	8
641	Decavanadate interactions with the elements of the SARS-CoV-2 spike protein highlight the potential role of electrostatics in disrupting the infectivity cycle. Journal of Inorganic Biochemistry, 2022, 234, 111899.	1.5	7
642	COVID-19 and the hidden threat of diabetic microvascular complications. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882211107.	1.4	1

#	Article	IF	Citations
643	Comparative Effectiveness of the SARS-CoV-2 Vaccines During Delta Dominance. SSRN Electronic Journal, 0, , .	0.4	0
645	Cleavageâ€Responsive Biofactory T Cells Suppress Infectious Diseasesâ€Associated Hypercytokinemia. Advanced Science, 2022, 9, .	5.6	1
647	Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). Pathology, 2022, , .	0.3	0
648	Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nature Communications, 2022, 13, .	5.8	42
649	Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccinesâ€"Effectiveness in Delta Variant Breakthrough Infections. Viruses, 2022, 14, 1385.	1.5	1
650	Assessment of the Humoral Immune Response Following COVID-19 Vaccination in Healthcare Workers: A One Year Longitudinal Study. Biomedicines, 2022, 10, 1526.	1.4	5
651	Post-acute infection syndrome after COVID-19: effects on the oral and maxillofacial region and the recent publication trends. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2022, 48, 131-132.	0.3	0
652	Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2. Npj Vaccines, 2022, 7, .	2.9	7
654	Association between Recent Usage of Antibiotics and Immunogenicity within Six Months after COVID-19 Vaccination. Vaccines, 2022, 10, 1122.	2.1	12
655	Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study. BMJ Open, 2022, 12, e057281.	0.8	1
656	T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine. , 2022, 10, e004953.		7
657	Clinical characteristics and outcomes of healthcare workers with COVIDâ€19 preâ€and postvaccination. Journal of Medical Virology, 2022, 94, 5279-5283.	2.5	6
658	COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy. Vaccines, 2022, 10, 1137.	2.1	6
659	SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge â€" Denver, Colorado, and San Diego, California, Januaryâ€"April 2021. Vaccine, 2022, 40, 4845-4855.	1.7	2
660	Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Reports, 2022, 40, 111160.	2.9	9
661	Clinical grade <scp>ACE2</scp> as a universal agent to block <scp>SARSâ€CoV</scp> â€2 variants. EMBO Molecular Medicine, 2022, 14, .	3.3	35
662	Optimized infection control practices augment the robust protective effect of vaccination for ESRD patients during a hemodialysis facility SARS-CoV-2 outbreak. American Journal of Infection Control, 2022, 50, 1118-1124.	1.1	4
663	Pediatric and adolescent COVIDâ€19 vaccination side effects: A retrospective cohort study of the Iranian teenage group in 2021. Journal of Medical Virology, 2022, 94, 4890-4900.	2.5	11

#	Article	IF	Citations
664	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
665	The impact of COVID 19 on the outcomes of thrombectomy in stroke patients: A systematic review and metaâ€analysis. Reviews in Medical Virology, 2023, 33, .	3.9	3
666	Guardians of the oral and nasopharyngeal galaxy: <scp>IgA</scp> and protection against <scp>SARSâ€CoV</scp>â€2 infection*. Immunological Reviews, 2022, 309, 75-85.	2.8	32
667	The interplay of post-acute COVID-19 syndrome and aging: a biological, clinical and public health approach. Ageing Research Reviews, 2022, 81, 101686.	5.0	6
668	The pandemic toll and post-acute sequelae of SARS-CoV-2 in healthcare workers at a Swiss University Hospital. Preventive Medicine Reports, 2022, 29, 101899.	0.8	1
669	Investigation of the diagnostic performance of the SARS-CoV-2 saliva antigen test: A meta-analysis. Journal of Microbiology, Immunology and Infection, 2022, 55, 1084-1093.	1.5	4
670	COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study. Scientific Reports, 2022, 12, .	1.6	5
671	Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination. Biosafety and Health, 2022, 4, 228-233.	1.2	6
672	Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose. Wellcome Open Research, 0, 7, 181.	0.9	4
673	Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. BMJ Open Respiratory Research, 2022, 9, e001268.	1.2	7
674	Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study. Frontiers in Medicine, 0, 9, .	1.2	1
675	Immunity waning after COVID vaccine booster vs. infectionâ€”better than expected. Infectious Diseases, 2022, 54, 828-831.	1.4	3
676	The effect of herd immunity thresholds on willingness to vaccinate. Humanities and Social Sciences Communications, 2022, 9, .	1.3	3
677	Comparative performance of COVID-19 serology testing. Practical Laboratory Medicine, 2022, 31, e00289.	0.6	0
678	Long-term observation of antibody titers against SARS-CoV-2 following vaccination. Public Health in Practice, 2022, 4, 100297.	0.7	1
679	Aspectos clÃnicos de la COVID-19. Ambiociencias, 0, , 7-22.	0.0	0
680	Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China. Expert Review of Vaccines, 2022, 21, 1465-1473.	2.0	3
681	The Advantages of the Zero-COVID-19 Strategy. International Journal of Environmental Research and Public Health, 2022, 19, 8767.	1.2	14

#	Article	IF	Citations
682	Clinical Effectiveness of SARS-CoV-2 Vaccination in Renal Transplant Recipients. Antibody Levels Impact in Pneumonia and Death. Transplantation, 2022, 106, e476-e487.	0.5	6
683	COVID-19 Vaccine for Children: Vaccination Willingness of Parents and Its Associated Factorsâ€"A Network Analysis. Vaccines, 2022, 10, 1155.	2.1	7
684	A SARS-CoV-2 Negative Antigen Rapid Diagnostic in RT-qPCR Positive Samples Correlates With a Low Likelihood of Infectious Viruses in the Nasopharynx. Frontiers in Microbiology, 0, 13, .	1.5	4
685	Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. EBioMedicine, 2022, 82, 104141.	2.7	11
686	COVID-19 Vaccination in China: Adverse Effects and Its Impact on Health Care Working Decisions on Booster Dose. Vaccines, 2022, 10, 1229.	2.1	8
687	Symptoms in the Long Period after the Coronavirus Infection: Results of Long-Term Follow-Up. Russian Archives of Internal Medicine, 2022, 12, 302-309.	0.0	0
688	Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1â€"August 20, 2021): a retrospective observational monocentric study. BMC Infectious Diseases, 2022, 22, .	1.3	2
689	Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers. Journal of Infection and Chemotherapy, 2022, 28, 1478-1482.	0.8	3
690	SARS-CoV-2 S2â€"targeted vaccination elicits broadly neutralizing antibodies. Science Translational Medicine, 2022, 14, .	5.8	57
691	SARS-CoV-2 Breakthrough Infections: Incidence and Risk Factors in a Large European Multicentric Cohort of Health Workers. Vaccines, 2022, 10, 1193.	2.1	19
692	Anti-TNFÎ± Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. Vaccines, 2022, 10, 1186.	2.1	8
693	COVID-19 After Vaccination in Lung Transplant Recipients: Real-Life Data. Experimental and Clinical Transplantation, 0, , .	0.2	0
694	Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection. PLoS ONE, 2022, 17, e0272056.	1.1	1
695	Melatonin: Regulation of Viral Phase Separation and Epitranscriptomics in Post-Acute Sequelae of COVID-19. International Journal of Molecular Sciences, 2022, 23, 8122.	1.8	7
696	Elevenâ€month longitudinal study of antibodies in SARSâ€CoVâ€2 exposed and naÃ¯ve primary health care workers upon COVIDâ€19 vaccination. Immunology, 2022, 167, 528-543.	2.0	2
697	Fifteen-Month Follow-Up of Anti-Spike Receptor-Binding Domain SARS-CoV-2 Antibodies among Healthcare Workers in Boston, MA. journal of applied laboratory medicine, The, 2022, 7, 1430-1437.	0.6	1
698	Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study. Annals of the Rheumatic Diseases, 2022, 81, 1594-1602.	0.5	22
699	SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. Annals of the Rheumatic Diseases, 2022, 81, 1585-1593.	0.5	12

#	Article	IF	Citations
701	SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research. Oncologist, 0, , .	1.9	0
702	The SARS-CoV-2 Variants and their Impacts. Journal of Pure and Applied Microbiology, 2022, 16, 1409-1424.	0.3	3
703	Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2. Biomedicines, 2022, 10, 1993.	1.4	8
704	Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response. Vaccines, 2022, 10, 1281.	2.1	11
705	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. Frontiers in Immunology, 0, 13, .	2.2	13
706	Evaluation of the effect of Loigolactobacillus coryniformis K8 CECT 5711 consumption in health care workers exposed to COVID-19. Frontiers in Nutrition, 0, 9, .	1.6	7
707	Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes. Nature Communications, 2022, 13, .	5.8	2
708	COVID-19 Outcomes and Risk Factors Among People Living with HIV. Current HIV/AIDS Reports, 2022, 19, 425-432.	1.1	35
709	Downâ€regulation of SARSâ€CoVâ€2 neutralizing antibodies in vaccinated smokers. MedComm, 2022, 3, .	3.1	3
710	Antibody titers among healthcare workers for coronavirus disease 2019 at 6Âmonths after BNT162b2 vaccination. Vaccine, 2022, , .	1.7	1
711	Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. Npj Vaccines, 2022, 7, .	2.9	68
712	Antiviral effect of cetylpyridinium chloride in mouthwash on SARS-CoV-2. Scientific Reports, 2022, 12, .	1.6	15
713	Analysis of contact tracing surveillance for COVID-19 among healthcare workers in secondary referral hospital, Indonesia. F1000Research, 0, 11, 506.	0.8	0
715	The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China. Frontiers in Public Health, 0, 10, .	1.3	5
716	Breakthrough COVID-19 infection according to the infectious diseases hospital. Kazan Medical Journal, 2022, 103, 541-551.	0.1	1
717	COVID-19 forecasting using new viral variants and vaccination effectiveness models. Computers in Biology and Medicine, 2022, 149, 105986.	3.9	14
718	A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients. Viruses, 2022, 14, 1822.	1.5	25
719	Time-Varying Effect of Hybrid Immunity on the Risk of Breakthrough Infection after Booster Dose of mRNA COVID-19 Vaccine: The MOSAICO Study. Vaccines, 2022, 10, 1353.	2.1	9

#	Article	IF	Citations
720	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nature Communications, 2022, 13, .	5.8	27
721	Bridging Animal and Human Data in Pursuit of Vaccine Licensure. Vaccines, 2022, 10, 1384.	2.1	3
722	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. Journal of Experimental Medicine, 2022, 219, .	4.2	12
723	Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis. Renal Replacement Therapy, 2022, 8, .	0.3	7
724	Analysis and Recommendations on Implementation of Non-Pharmaceutical Interventions in Different Countries under COVID-19. , 0, 8, 635-643.		0
725	Rapid Rollout and Initial Uptake of a Booster COVID-19 Vaccine Among Israel Defense Forces Soldiers. , 0, , .		3
726	From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell, 2022, 185, 3086-3103.	13.5	57
727	Statistical and agent-based modelling of the transmissibility of different SARS-CoV-2 variants in England and impact of different interventions. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2022, 380, .	1.6	11
729	Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. Lancet Regional Health - Europe, The, 2022, 21, 100479.	3.0	29
730	A study of SARS-CoV-2 delta variant breakthrough infections and side effects of the Oxford-AstraZeneca vaccine. Public Health in Practice, 2022, 4, 100303.	0.7	8
731	A novel logarithmic approach to generate new probability distributions for data modeling in the engineering sector. AEJ - Alexandria Engineering Journal, 2023, 62, 313-325.	3.4	8
732	Excess Mortality among Physicians and Dentists during COVID-19 in Italy: A Cross-Sectional Study Related to a High-Risk Territory. Healthcare (Switzerland), 2022, 10, 1684.	1.0	4
734	SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays. Diagnostic Microbiology and Infectious Disease, 2022, 104, 115803.	0.8	8
735	Vaccine breakthrough infections with SARS-CoV-2: Why older adults need booster vaccinations. Public Health in Practice, 2022, 4, 100307.	0.7	3
736	COVID-19 post-vaccination in healthcare workers and vaccine effectiveness, Brazil, 2021. Clinics, 2022, 77, 100109.	0.6	1
737	COVID-19 breakthrough infections amongst ChAdOx1 nCoV-19 (Covishield) vaccinated health-care workers and its clinical manifestations: A prospective observational study. Journal of Marine Medical Society, 2022, 24, 154.	0.0	0
738	COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments. Advances in Infectious Diseases, 2022, 12, 568-631.	0.0	1
739	SARS-CoV-2 Infection upon Leaving the Tokyo 2020 Olympic and Paralympic Games. Internal Medicine, 2022, 61, 3659-3666.	0.3	2

#	Article	IF	Citations
740	Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. PLoS ONE, 2022, 17, e0273712.	1.1	4
741	Prognosis of COVID-19 in the middle eastern population, knowns and unknowns. Frontiers in Microbiology, 0, 13, .	1.5	1
742	Superspreading event of Covid-19 in adolescents: is there a difference between the vaccinated and the unvaccinated?. Salud Publica De Mexico, 2022, 64, 446-447.	0.1	0
743	Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021. Journal of the Formosan Medical Association, 2022, 121, 2438-2445.	0.8	4
744	Transition of Antibody Titers after SARS-CoV-2 mRNA Vaccination in Japanese Healthcare Workers. Japanese Journal of Infectious Diseases, 2023, 76, 72-76.	0.5	4
745	Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. Archives of Public Health, 2022, 80, .	1.0	30
746	Epidemiological and Serological Analysis of a SARS-CoV-2 Outbreak in a Nursing Home: Impact of SARS-CoV-2 Vaccination and Enhanced Neutralizing Immunity Following Breakthrough Infection. Microorganisms, 2022, 10, 1809.	1.6	2
747	Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK). Vaccines, 2022, 10, 1601.	2.1	20
748	Acceptance of COVID-19 Vaccine Booster Doses Using the Health Belief Model: A Cross-Sectional Study in Low-Middle- and High-Income Countries of the East Mediterranean Region. International Journal of Environmental Research and Public Health, 2022, 19, 12136.	1.2	28
749	Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital. Journal of Osteopathic Medicine, 2022, 122, 635-640.	0.4	4
750	An uncertain time: Clinical nurses' first impressions during the COVIDâ€19 pandemic. Research in Nursing and Health, 2022, 45, 537-548.	0.8	6
751	Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination. IScience, 2022, 25, 105209.	1.9	2
752	Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses. Jacs Au, 2022, 2, 2187-2202.	3.6	4
753	Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. PLoS Pathogens, 2022, 18, e1010802.	2.1	27
755	Genetic Load of SARS-CoV-2 in Aerosols Collected in Operating Theaters. Applied and Environmental Microbiology, 2022, 88, .	1.4	2
756	A Newly Developed Interprofessional In-Situ Simulation-Based Training for Airway Management of COVID-19 Patients: Identification of Challenges and Safety Gaps, and Assessment of the Participantsâ€™ Reaction. Journal of Clinical Medicine Research, 2022, 14, 377-387.	0.6	0
757	Longitudinal Comparison of Neutralizing Antibody Responses to COVID-19 mRNA Vaccines after Second and Third Doses. Vaccines, 2022, 10, 1459.	2.1	3
760	COVID 19 breakthrough infections in vaccinated dental student community of North Kerala- A survey based analysis. International Journal of Oral Health Dentistry, 2022, 8, 216-221.	0.0	0

#	Article	IF	Citations
761	Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 2022, 8, e002587.	1.8	21
762	Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. JAMA Network Open, 2022, 5, e2231778.	2.8	77
763	Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection. Cell Reports Medicine, 2022, 3, 100764.	3.3	16
764	Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood, 2022, 140, 2773-2787.	0.6	40
765	Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Microbiology Spectrum, 2022, 10, .	1.2	19
766	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. Medicine (United States), 2022, 101, e30609.	0.4	4
767	Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination. Frontiers in Immunology, 0, 13, .	2.2	8
768	Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection. Med, 2022, 3, 827-837.e3.	2.2	13
769	Long-COVID Syndrome and the Cardiovascular System: A Review of Neurocardiologic Effects on Multiple Systems. Current Cardiology Reports, 2022, 24, 1711-1726.	1.3	15
770	An Update on Complications Associated with SARS-CoV-2 Infection and COVID-19 Vaccination. Vaccines, 2022, 10, 1639.	2.1	1
771	Shedding of infectious SARS-CoV-2 despite vaccination. PLoS Pathogens, 2022, 18, e1010876.	2.1	36
772	The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity. International Journal of Molecular Sciences, 2022, 23, 11325.	1.8	6
773	<scp>Multiâ€disciplinary</scp> collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with <scp>postâ€acute</scp> sequelae of <scp>SARSâ€CoV</scp>â€2 infection (<scp>PASC</scp>). PM and R, 2022, 14, 1270-1291.	0.9	26
774	Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants. Microbiology Spectrum, 2022, 10, .	1.2	3
775	Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152). IJID Regions, 2022, 5, 104-110.	0.5	4
776	COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness. Viruses, 2022, 14, 2086.	1.5	12
777	Severe breakthrough <scp>COVID</scp>â€19 infections in vaccinated patients with schizophrenia in Israel. World Psychiatry, 2022, 21, 471-472.	4.8	7
778	Mucosal plasma cells are required to protect the upper airway and brain from infection. Immunity, 2022, 55, 2118-2134.e6.	6.6	26

#	Article	IF	Citations
779	Disease Severity in Vaccinated Adults Hospitalized with Breakthrough COVID-19. Hospital Topics, 0, , 1-8.	0.3	0
780	Correlation of Breakthrough Infection During the Omicron Wave With Seropositivity of Vaccinated Patients Undergoing Hemodialysis. Cureus, 2022, , .	0.2	0
781	Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	8
782	Assessment of Predictors for SARS-CoV-2 Antibodies Decline Rate in Health Care Workers after BNT162b2 Vaccinationâ€"Results from a Serological Survey. Vaccines, 2022, 10, 1443.	2.1	1
783	Disease profile and patient outcomes in vaccinated COVID-19 patients. Medical Journal Armed Forces India, 2022, , .	0.3	0
784	Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer. Cell Reports Medicine, 2022, 3, 100781.	3.3	15
786	The New Generation of Contact Tracing Solution: The Case of Morocco. Lecture Notes on Data Engineering and Communications Technologies, 2023, , 432-443.	0.5	0
787	Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection. Vaccines, 2022, 10, 1548.	2.1	25
788	Vaccineâ€induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. Journal of Medical Virology, 2023, 95, .	2.5	19
789	Uptake of COVID-19 booster shot among healthcare workers: A mediation analysis approach. Frontiers in Public Health, 0, 10, .	1.3	5
790	The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controlsâ€"a prospective cohort study. BMC Medicine, 2022, 20, .	2.3	8
791	COVID-19 Breakthrough Infections among Patients with Cancer Receiving Sinopharm BIBP Vaccine. International Journal of Cancer Management, 2022, 15, .	0.2	0
792	The Relationship Between Anti-Spike SARS-CoV-2 Antibody Levels and Risk of Breakthrough COVID-19 Among Fully Vaccinated Adults. Journal of Infectious Diseases, 2023, 227, 339-343.	1.9	9
793	Ad5â€nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants. Journal of Medical Virology, 2023, 95, .	2.5	10
794	Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients. Nature Communications, 2022, 13, .	5.8	3
795	The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data. JMIR Public Health and Surveillance, 2022, 8, e38898.	1.2	4
796	No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers. Journal of Infection, 2022, 85, e177-e180.	1.7	6
797	A multicenter international prospective study of the validity and reliability of a COVID-19-specific health-related quality of life questionnaire. Quality of Life Research, 0, , .	1.5	0

#	Article	IF	Citations
798	SARS-CoV-2 Vaccination in Kidney Transplant Recipientsâ€"Stratified Analysis of the Humoral Immune Response. Transplantation Direct, 2022, 8, e1384.	0.8	5
799	COVID-19 Breakthrough Infections among Patients Aged â‰¥65 Years in Serbia: Morbidity and Mortality Overview. Vaccines, 2022, 10, 1818.	2.1	7
800	Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature Medicine, 2023, 29, 147-157.	15.2	32
801	Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination. Vaccines, 2022, 10, 1784.	2.1	1
802	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. Journal of Pharmaceutical Analysis, 2023, 13, 1-10.	2.4	1
803	Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PFâ€07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARSâ€CoVâ€2, in Healthy Adult Participants. Clinical Pharmacology in Drug Development, 2022, 11, 1382-1393.	0.8	4
804	Trial by media: evaluating the role of mainstream media and fact-checking agencies during the COVID-19 pandemic. International Journal of Human Rights in Healthcare, 2022, ahead-of-print, .	0.6	0
805	Local monitoring of SARS-CoV-2 variants in two large California counties in 2021. Scientific Reports, 2022, 12, .	1.6	0
806	COVID-19 Infection after vaccination among Healthcare Workers at a Tertiary Level Health Care Center in Northern India: A Cross-Sectional Study. Recent Advances in Anti-Infective Drug Discovery, 2022, 17, .	0.4	0
807	Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study. Minerva Gastroenterology, 0, , .	0.3	0
808	The Waning of BNT162b2 Vaccine Effectiveness for SARS-CoV-2 Infection Prevention over Time: A Test-Negative Study in Health Care Professionals of a Health Department from January 2021 to December 2021. International Journal of Environmental Research and Public Health, 2022, 19, 13884.	1.2	1
809	Individual-based modeling reveals that the COVID-19 isolation period can be shortened by community vaccination. Scientific Reports, 2022, 12, .	1.6	3
810	Outliers Matterâ€"Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies. Microorganisms, 2022, 10, 2067.	1.6	2
811	Sensitivity analysis of rapid antigen tests for the Omicron SARS-CoV-2 variant detection from nasopharyngeal swab samples collected in Santiago of Chile. Frontiers in Public Health, 0, 10, .	1.3	1
812	Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review. Expert Review of Anti-Infective Therapy, 0, , 1-11.	2.0	3
814	Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients. Vaccine, 2022, 40, 6971-6978.	1.7	8
815	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. Infectious Diseases, 0, , .	4.0	0
816	Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. RMD Open, 2022, 8, e002417.	1.8	12

#	Article	IF	Citations
817	Preferences and willingness of accepting COVID-19 vaccine booster: Results from a middle-income country. Vaccine, 2022, 40, 7515-7519.	1.7	5
818	Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine. Journal of Infection, 2022, , .	1.7	0
819	A systematic survey of adultsâ€™ health-protective behavior use during early COVID-19 pandemic in Canada, Germany, United Kingdom, and the United States, and vaccination hesitancy and status eight months later. Preventive Medicine Reports, 2022, 30, 102013.	0.8	2
820	Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2022, 68, 104371.	0.9	7
821	Likelihood of COVID-19 reinfection in an urban community cohort in Massachusetts. , 2022, 1, 100057.		0
822	Risk factors for critical forms of SARS-CoV-2 infection in fully vaccinated patients: a prospective observational study. Pan African Medical Journal, 0, 43, .	0.3	1
823	Antibody Dependent Enhancement of SARS-CoV-2 Infection in the Era of Rapid Vaccine Development. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2022, 76, 383.	0.4	1
824	Ai Chi for Long COVID: Transitioning to a Post-Rehabilitation Community Program. , 2022, 30, 60-64.		0
825	COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19). Cancers, 2022, 14, 5547.	1.7	1
826	Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey. Scientific Reports, 2022, 12, .	1.6	4
827	Why Molnupiravir Fails in Hospitalized Patients. MBio, 2022, 13, .	1.8	4
829	Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Viruses, 2022, 14, 2540.	1.5	33
830	Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination. Cell Reports Medicine, 2022, 3, 100845.	3.3	6
831	Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice. Nature Communications, 2022, 13, .	5.8	8
833	The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases, 2023, 76, 1315-1317.	2.9	8
834	Modelling COVID-19 vaccine breakthrough infections in highly vaccinated Israelâ€”The effects of waning immunity and third vaccination dose. PLOS Global Public Health, 2022, 2, e0001211.	0.5	11
835	Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	11
836	Do vaccination is an effective therapeutic option for long COVID?. , 0, 1, 14.		0

#	Article	IF	Citations
837	Human Coronaviruses. , 2023, , 1167-1175.e6.		0
838	Recombinant proteins of spike protein of SARS-CoV-2 with the Omicron receptor-binding domain induce production of highly Omicron-specific neutralizing antibodies. Clinical and Experimental Vaccine Research, 2022, 11, 285.	1.1	1
839	Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination. Journal of Theoretical Biology, 2023, 559, 111384.	0.8	7
840	Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211418.	1.0	4
841	SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses. AIMS Microbiology, 2022, 8, 422-453.	1.0	1
842	Twittersâ€™ Concerns and Opinions About the COVID-19 Booster Shots: Infoveillance Study. Journal of Consumer Health on the Internet, 2022, 26, 337-356.	0.2	2
843	Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima. Vaccines, 2022, 10, 2007.	2.1	3
844	Severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections: A single metro-based testing network experience. Frontiers in Medicine, 0, 9, .	1.2	0
845	Impact of COVID-19 Vaccination on Seroprevalence of SARS-CoV-2 among the Health Care Workers in a Tertiary Care Centre, South India. Vaccines, 2022, 10, 1967.	2.1	3
846	Weakened humoral and cellular immune response to the inactivated COVID-19 vaccines in Chinese individuals with obesity/overweight. Genes and Diseases, 2023, 10, 608-617.	1.5	5
847	Clinical Chemistry and Laboratory Medicine celebrates 60 yearsÂâ€“ narrative review devoted to the contribution of the journal to the diagnosis of SARS-CoV-2. Clinical Chemistry and Laboratory Medicine, 2023, 61, 811-821.	1.4	7
848	Post-vaccination adverse reactions, decision regret, and willingness to pay for the booster dose of COVID-19 vaccine among healthcare workers: A mediation analysis. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
849	Optimizing national border reopening policies in the COVID-19 pandemic: A modeling study. Frontiers in Public Health, 0, 10, .	1.3	0
850	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. Frontiers in Microbiology, 0, 13, .	1.5	5
851	Post-acute sequelae of COVID-19 among hospitalized patients in Estonia: Nationwide matched cohort study. PLoS ONE, 2022, 17, e0278057.	1.1	8
852	SARS-CoV-2 infection outcomes associated with the Delta variant: A prospective cohort study. Jammi, 2023, 8, 49-56.	0.3	3
853	Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. Frontiers in Medicine, 0, 9, .	1.2	2
854	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. Stem Cell Reviews and Reports, 0, , .	1.7	2

#	Article	IF	Citations
855	The role of Israeli researchers in the scientific literature regarding COVID-19 vaccines. Israel Journal of Health Policy Research, 2022, 11, .	1.4	2
857	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
858	An Evaluation of Serological Tests to Determine Postvaccinal Immunity to SARS-CoV-2 by mRNA Vaccines. Journal of Clinical Medicine, 2022, 11, 7534.	1.0	0
860	High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya. PLoS ONE, 2022, 17, e0272751.	1.1	4
861	A Cross Sectional Study on Adherence to COVID Appropriate Behaviour and Contributing Factors among Vaccinated Individuals Attending ENT Out-Patient Department of a Teaching Hospital in India. Bengal Journal of Otolaryngology and Head Neck Surgery, 2022, 30, 70-79.	0.1	0
862	SARS-CoV-2 infection among healthcare workers whom already received booster vaccination during epidemic outbreak of omicron variant in Taiwan. Journal of the Formosan Medical Association, 2022, , .	0.8	4
863	One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine. Vaccine, 2022, , .	1.7	4
864	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. Journal of Taibah University Medical Sciences, 2023, 18, 600-638.	0.5	1
865	Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity. Journal of Infectious Diseases, 2023, 227, 780-787.	1.9	10
866	Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. Clinical Infectious Diseases, 2023, 76, 1403-1411.	2.9	52
867	The impact of COVID-19 vaccination campaign in Hong Kong SAR China and Singapore. Infectious Disease Modelling, 2023, 8, 101-106.	1.2	5
868	Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. International Immunology, 2023, 35, 213-220.	1.8	6
869	Knowledge, attitudes, and behaviors regarding COVID-19 among hospitalized patients in Taizhou, China. Zeitschrift Fur Gesundheitswissenschaften, 2024, 32, 137-143.	0.8	0
870	Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19. Microbes and Infection, 2023, 25, 105082.	1.0	5
871	Breakthrough Infections: Clinical Profile and Outcomes of COVID-19 Vaccinated and Unvaccinated People From a Tertiary Care Hospital. Cureus, 2022, , .	0.2	1
872	Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel. Journal of Hospital Infection, 2022, , .	1.4	4
873	Vaccinated Healthcare Workersâ€™ Adherence to COVID-19 Prevention Measures and Associated Factors in Northwest Ethiopia: A Facility-Based Cross-Sectional Study. Risk Management and Healthcare Policy, 0, Volume 15, 2389-2398.	1.2	0
874	Analysis of research hotspots in COVID-19 genomics based on citespace software: Bibliometric analysis. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	4

#	Article	IF	Citations
875	SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test. Life, 2022, 12, 2064.	1.1	0
876	Recent developments in the immunopathology of <scp>COVID</scp>â€19. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 369-388.	2.7	33
877	Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients. Transplantation Direct, 2023, 9, e1401.	0.8	8
878	Mixed formulation of mRNA and proteinâ€based COVIDâ€19 vaccines triggered superior neutralizing antibody responses. MedComm, 2022, 3, .	3.1	1
879	Long-Term Dynamic of Anti-TrimericS and Anti-RBD Antibodies in Naive and COVID-19 Recovered mRNA-1273 Vaccine Recipients. Laboratory Medicine, 0, , .	0.8	0
880	High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients. Viruses, 2022, 14, 2769.	1.5	4
881	Good Immunogenicity of Delayed Second Dose of BNT162b2 Vaccine in Individuals with Acute Allergic-like Reactions after the First Dose. Reports, 2022, 5, 48.	0.2	0
882	Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up. Nature Communications, 2022, 13, .	5.8	18
883	Current and Emerging Knowledge in COVID-19. Radiology, 2023, 306, .	3.6	30
884	Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization. IScience, 2023, 26, 105969.	1.9	6
885	Functionalized Fullerene for Inhibition of SARSâ€CoVâ€2 Variants. Small, 2023, 19, .	5.2	8
886	Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients. Viruses, 2023, 15, 253.	1.5	2
887	SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India. Frontiers in Public Health, 0, 10, .	1.3	3
888	Aligning staff schedules, testing, and isolation reduces the risk of COVID-19 outbreaks in carceral and other congregate settings: A simulation study. PLOS Global Public Health, 2023, 3, e0001302.	0.5	1
889	Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. Frontiers in Immunology, 0, 13, .	2.2	1
890	Response to COVID-19 in Lebanon: update, challenges and lessons learned. Epidemiology and Infection, 2023, 151, .	1.0	12
892	SARS-CoV-2 Breakthrough Infections in Health Care Workers: An Italian Retrospective Cohort Study on Characteristics, Clinical Course and Outcomes. Journal of Clinical Medicine, 2023, 12, 628.	1.0	8
893	A generalized distributed delay model of COVID-19: An endemic model with immunity waning. Mathematical Biosciences and Engineering, 2023, 20, 5379-5412.	1.0	4

#	Article	IF	Citations
894	The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19. Transplant Immunology, 2023, 77, 101777.	0.6	0
895	Genetic Sequencing of Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Fully Vaccinated Healthcare Workers. Infectious Diseases in Clinical Practice, 2023, 31, .	0.1	0
896	A Study on The Efficacy of Vaccination in Elderly Patients with Breakthrough COVID-19 Infection. Korean Journal of Clinical Geriatrics, 2022, 23, 115-122.	0.3	0
898	Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer. JAMA Oncology, 2023, 9, 386.	3.4	23
899	Near-Complete SARS-CoV-2 Seroprevalence among Rural and Urban Kenyans despite Significant Vaccine Hesitancy and Refusal. Vaccines, 2023, 11, 68.	2.1	4
901	Higher COVID-19 Vaccination Rates Are Associated with Lower COVID-19 Mortality: A Global Analysis. Vaccines, 2023, 11, 74.	2.1	11
902	Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study. Vaccines, 2023, 11, 56.	2.1	4
903	The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study. Viruses, 2023, 15, 326.	1.5	1
904	Association of Lower Antispike Antibody Levels with Mortality in ICU Patients with COVID-19 Disease. Critical Care Research and Practice, 2023, 2023, 1-8.	0.4	0
905	Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern. Viruses, 2023, 15, 346.	1.5	4
906	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Frontiers in Immunology, 0, 14, .	2.2	14
907	COVID-19 Infection and Acute Pancreas Transplant Graft Thrombosis. Cureus, 2023, , .	0.2	0
909	Genomic surveillance of SARS-CoV-2 in COVID-19 vaccinated healthcare workers in Lebanon. BMC Medical Genomics, 2023, 16, .	0.7	4
911	COVID-19: Diabetes Perspectiveâ€"Pathophysiology and Management. Pathogens, 2023, 12, 184.	1.2	7
912	Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 2023, 14, .	2.7	4
913	MARKIZ study: screening for post-COVID-19 syndrome using a questionnaire to identify symptoms and risk factors for noncommunicable diseases. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf		
914	Severe Acute Respiratory Syndrome Related Coronavirus 2 (SARS-Cov2) Infection Among Doctors and Nurses After Introduction of Vaccination - A Tertiary Care Experience from Mumbai. International Journal of Medical Science and Clinical Research Studies, 2023, 03, .	0.0	0
915	Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. Bioengineering, 2023, 10, 148.	1.6	3

#	Article	IF	Citations
916	Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers. Vaccines, 2023, 11, 283.	2.1	3
917	Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2. Frontiers in Immunology, 0, 14, .	2.2	5
918	Role of vaccination and anti-SARS-CoV-2 antibodies in the clinical outcome of hospitalized COVID-19 patients. Medicina ClÃnica, 2023, 160, 476-483.	0.3	8
919	COVID-19 mRNA vaccine immunogenicity decay and breakthrough illness in adolescents and young adults with childhood-onset rheumatic diseases. Rheumatology, 2023, 62, 3101-3109.	0.9	1
920	Enzymatic approaches against SARS-CoV-2 infection with an emphasis on the telomere-associated enzymes. Biotechnology Letters, 0, , .	1.1	0
921	Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults. Journal of Infectious Diseases, 2023, 227, 1153-1163.	1.9	4
922	Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study. BMJ Open, 2023, 13, e063141.	0.8	10
923	Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks. Journal of Infectious Diseases, 2023, 228, 391-401.	1.9	13
924	Machine Learning and Intelligent Network System based Covid 19 Health Care System. , 2022, , .		0
925	Omicron Infections in Otolaryngology Practice: A Retrospective Observational Study on Testing, Symptoms and Vaccination Status. Advances in Infectious Diseases, 2023, 13, 81-95.	0.0	0
926	Antiâ€SARSâ€CoVâ€2 spike immunoglobulinÂG and immunoglobulinÂM titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients. Clinical Respiratory Journal, 0, , .	0.6	0
927	On Statistical Modeling Using a New Version of the Flexible Weibull Model: Bayesian, Maximum Likelihood Estimates, and Distributional Properties with Applications in the Actuarial and Engineering Fields. Symmetry, 2023, 15, 560.	1.1	2
928	Levels of SARS-COV-2 anti-spike protein receptor-binding domain (s-rbd) igg in indonesian vaccinated healthcare workers: experimental research. Annals of Medicine and Surgery, 0, Publish Ahead of Print, .	0.5	0
929	SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo. Microorganisms, 2023, 11, 1015.	1.6	8
930	Risk-adjusted Staffing Policies to Minimize Perioperative Staffing Shortages During a Pandemic: An Agent-Based Simulation Study. Epidemiology and Infection, 0, , 1-30.	1.0	0
931	Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021â€“August 2022. Emerging Infectious Diseases, 2023, 29, 723-733.	2.0	1
932	Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity. Journal of Virological Methods, 2023, 316, 114728.	1.0	1
933	Development of SARS-CoV-2 neutralizing antibody detection assay by using recombinant plant-produced proteins. Biotechnology Reports (Amsterdam, Netherlands), 2023, 38, e00796.	2.1	2

#	Article	IF	Citations
934	Longitudinal analysis of anti-SARS-CoV-2 neutralizing antibody (NAb) titers in vaccinees using a novel giant magnetoresistive (GMR) assay. Sensors and Actuators B: Chemical, 2023, 387, 133773.	4.0	1
935	Aptamers dimerization inspired biomimetic clamp assay towards impedimetric SARS-CoV-2 antigen detection. Sensors and Actuators B: Chemical, 2023, 380, 133387.	4.0	5
936	Antibody titer levels and the effect on subsequent SARS-CoV-2 infection in a large US-based cohort. Heliyon, 2023, 9, e13103.	1.4	4
937	Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine, 2023, 41, 1925-1933.	1.7	11
938	Evaluation of Antibody Response to Biontech and Sinovac Vaccines Applied in Our Region. KahramanmaraÅŸ SÃ¼tÃ§Ã¼ Ä°mam Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 2023, 18, 115-119.	0.1	0
939	Molnupiravir is effective in patients with haematological malignancies. International Journal of Cancer, 2023, 153, 1251-1256.	2.3	3
940	Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerging Infectious Diseases, 2023, 29, 381-388.	2.0	42
941	COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis. Respiratory Investigation, 2023, 61, 220-229.	0.9	2
942	Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants. Journal of Infectious Diseases, 2023, 227, 1164-1172.	1.9	5
943	SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants. Pathogens, 2023, 12, 244.	1.2	8
944	The association of neonatal SARS-CoV-2 anti-spike protein receptor-binding domain antibodies at delivery with infant SARS-CoV-2 infection under the age of 6Âmonths: a prospective cohort study. Clinical Microbiology and Infection, 2023, 29, 789-794.	2.8	2
945	SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection. Nature Communications, 2023, 14, .	5.8	25
946	Effect of COVID-19 Vaccination on the Levels of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Naive, Hybrid, and Breakthrough SARS-CoV-2 Recovered Indian Individuals. Journal of Laboratory Physicians, 0, , .	0.4	0
947	Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. Open Forum Infectious Diseases, 2023, 10, .	0.4	0
948	Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients. American Journal of Transplantation, 2023, 23, 649-658.	2.6	12
950	Risk of VTE in Nonrespiratory and Respiratory Presentations of COVID-19 in Critically Ill Patients. Chest, 2023, , .	0.4	0
951	Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. Frontiers in Immunology, 0, 14, .	2.2	2
952	Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19. Npj Vaccines, 2023, 8, .	2.9	2

#	Article	IF	Citations
953	Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. Open Forum Infectious Diseases, 2023, 10, .	0.4	4
954	Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium. The Lancet Regional Health Americas, 2023, 19, 100445.	1.5	11
955	Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru. Vaccines, 2023, 11, 447.	2.1	2
957	Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. Viruses, 2023, 15, 549.	1.5	3
958	A Synthetic Biology Approach for Vaccine Candidate Design against Delta Strain of SARS-CoV-2 Revealed Disruption of Favored Codon Pair as a Better Strategy over Using Rare Codons. Vaccines, 2023, 11, 487.	2.1	6
959	Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis. Microbiology Spectrum, 2023, 11, .	1.2	3
960	The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection. Annals of Medicine, 2023, 55, 722-732.	1.5	0
961	SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. Viruses, 2023, 15, 639.	1.5	1
963	Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms. Annals of Hematology, 2023, 102, 819-827.	0.8	2
964	Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients. Vaccines, 2023, 11, 572.	2.1	3
965	Â«Long COVIDÂ»: the current state of the problem. A review of foreign scientific and medical publications. Physical and Rehabilitation Medicine Medical Rehabilitation, 2023, 5, 52-79.	0.1	0
966	Higher plasma levels of thymosin-Î±1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home. Immunity and Ageing, 2023, 20, .	1.8	1
967	Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination. Npj Vaccines, 2023, 8, .	2.9	0
968	Changes in parents' attitudes towards childhood vaccines during <scp>COVID</scp>â€19 pandemic. Pediatrics International, 2023, 65, .	0.2	1
969	Clinical features and severe outcome predictors of COVID-19 vaccine breakthrough infection among hospitalized patients: results from Egypt severe acute respiratory infections sentinel surveillance, 2021â€“2022. BMC Infectious Diseases, 2023, 23, .	1.3	1
970	Factors Associated With Nosocomial COVID-19 Infection Among Health Care Workers in an Urban-Setting Malaysia Hospital. Asia-Pacific Journal of Public Health, 0, , 101053952311592.	0.4	0
971	"Sinopharm", "Oxford-AstraZeneca", and "Pfizer-BioNTech" COVID-19 vaccinations: testing efficacy using lung CT-volumetry with comparative analysis of variance (ANOVA). Egyptian Journal of Radiology and Nuclear Medicine, 2023, 54, .	0.3	0
972	Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. JCI Insight, 2023, 8, .	2.3	1

#	Article	IF	Citations
973	Quality of life of earlyâ€stage breastâ€cancer patients diagnosed with COVIDâ€19 in the first three waves of the epidemic treated in the Spanish region of Navarre. Psycho-Oncology, 2023, 32, 730-740.	1.0	2
974	Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection. Nature Genetics, 2023, 55, 471-483.	9.4	14
975	Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies. International Journal of Molecular Sciences, 2023, 24, 5352.	1.8	7
976	Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up. Clinical Microbiology and Infection, 2023, 29, 918-923.	2.8	3
977	T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis. Vaccines, 2023, 11, 653.	2.1	5
978	Effectiveness and adverse effects of astrazeneca and pfizer COVID-19 vaccines among medical students in Oman: A comparative study. Biomedical and Biotechnology Research Journal, 2023, 7, 101.	0.3	1
979	Prior SARS-CoV-2 infection enhances and reshapes spike proteinâ€“specific memory induced by vaccination. Science Translational Medicine, 2023, 15, .	5.8	15
980	Challenges and Recent Advancements in COVID-19 Vaccines. Microorganisms, 2023, 11, 787.	1.6	1
981	Death Reporting in Breakthrough and Unvaccinated SARS-CoV-2 Infection Cases. Disaster Medicine and Public Health Preparedness, 2023, 17, .	0.7	0
982	Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe, The, 2023, 4, e309-e318.	3.4	26
983	Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19. Frontiers in Immunology, 0, 14, .	2.2	3
984	Curcumin Confers Anti-Inflammatory Effects in Adults Who Recovered from COVID-19 and Were Subsequently Vaccinated: A Randomized Controlled Trial. Nutrients, 2023, 15, 1548.	1.7	5
985	Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nature Communications, 2023, 14, .	5.8	31
986	Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. Nature Communications, 2023, 14, .	5.8	8
987	COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 2023, 111, 211-229.	2.0	15
988	Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. Nature Communications, 2023, 14, .	5.8	6
989	Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens. Vaccines, 2023, 11, 744.	2.1	1
990	The Effect of the Immunization Schedule and Antibody Levels (Anti-S) on the Risk of SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers in Northern Italy. Vaccines, 2023, 11, 746.	2.1	4

#	Article	IF	Citations
991	Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. Vaccine, 2023, 41, 3003-3010.	1.7	1
992	COVID-19 burden and influencing factors in Swiss long-term-care facilities: a cross-sectional analysis of a multicentre observational cohort. Swiss Medical Weekly, 2023, 153, 40052.	0.8	0
993	Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing. Clinical Chemistry and Laboratory Medicine, 2023, 61, 1670-1675.	1.4	3
994	Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients. Vaccines, 2023, 11, 770.	2.1	0
995	Transmission and Risk Factors of COVID-19 among Health Care Workers. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 340-348.	0.8	3
996	Vaccination coverage and breakthrough infections of COVID-19 during the second wave among staff of selected medical institutions in India. PLOS Global Public Health, 2023, 3, e0000946.	0.5	2
997	Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions. Communications Biology, 2023, 6, .	2.0	4
998	Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. Vaccines, 2023, 11, 819.	2.1	0
999	Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study. Frontiers in Microbiology, 0, 14, .	1.5	3
1001	Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration. Clinical Chemistry and Laboratory Medicine, 2023, 61, 1875-1885.	1.4	3
1002	Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt. Egyptian Journal of Bronchology, 2023, 17, .	0.3	2
1003	Exploration on wastewater-based epidemiology of SARS-CoV-2: Mimic relative quantification with endogenous biomarkers as internal reference. Heliyon, 2023, 9, e15705.	1.4	1
1004	Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections. IScience, 2023, 26, 106716.	1.9	1
1055	Covid-19 (Infektion mit SARS-CoV-2). , 2023, , 519-531.		0
1058	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
1120	Olfactory immunology: the missing piece in airway and CNS defence. Nature Reviews Immunology, 0, , .	10.6	1
1127	Silent battles: immune responses in asymptomatic SARS-CoV-2 infection. , 2024, 21, 159-170.		3
1129	Structure-Based Screening of Potential Drugs against SARS-CoV-2 Variants. , 0, , .		0

#	Article	IF	Citations